TRANSKRIPT 🔗
WEBVTT
00:00:07.919 --> 00:00:16.559
Hello and welcome to the second season of Unifying Research, a podcast about bridging the gap between the business side and patient side of the research industry.
00:00:16.719 --> 00:00:18.800
I'm your host, Justin Osborne.
00:00:19.120 --> 00:00:25.519
I have the privilege of working with an amazing group of people at Univo IRB, the fastest growing IRB in the industry.
00:00:25.679 --> 00:00:32.159
At Univo, we believe patients should have a bigger voice so clinical trials are better and more accessible for all.
00:00:32.479 --> 00:00:41.600
So we're using our network and platform to not only give patients a voice, but also share industry expertise for those of us working to improve research from the inside.
00:00:41.920 --> 00:00:51.359
Each episode will have two conversations, one with a research professional discussing their area of expertise, and the other conversation on the patient side and experience with research.
00:00:51.600 --> 00:00:59.439
My hope is that these episodes will spark further conversations, creating opportunities to bridge the gap between patients and research.
00:00:59.759 --> 00:01:07.040
Quick disclaimer before we dive in: the opinions you hear on this podcast are our own and don't reflect those of our employers, past or present.
00:01:07.200 --> 00:01:14.480
We could be talking about research, data, regulations, or even laws that affect your organization, but this is not legal advice.
00:01:15.120 --> 00:01:18.640
My first guest on the research expert side is Michelle Markham.
00:01:18.799 --> 00:01:24.079
Michelle is currently the Senior Director of Clinical Research at the University of Cincinnati Cancer Center.
00:01:24.239 --> 00:01:37.920
With over two decades of experience across major academic medical centers, including Mayo Clinic and University of Kentucky, Michelle specializes in clinical research operations, quality oversight, building successful programs, and workforce development.
00:01:38.079 --> 00:01:43.519
I spoke with Michelle about her role on the administrative side of running a cancer clinical trials program.
00:01:43.760 --> 00:01:56.319
We talk about the infrastructure needed to support cancer clinical trials and how that infrastructure is guided by the larger, mission-led focus of ensuring more access to trials for patients in their community.
00:01:56.560 --> 00:02:06.560
It's a fascinating discussion that dives into the quote business side of research, but it's also refreshing to hear Michelle frame her work through the lens of the patient in their experience.
00:02:06.799 --> 00:02:11.360
It's always fun talking with good leaders, and I hope you enjoyed this conversation as much as I did.
00:02:11.520 --> 00:02:14.639
So without further ado, here's my discussion with Michelle.
00:02:16.879 --> 00:02:20.479
I am very excited to have Michelle Markham with me here on the podcast.
00:02:20.639 --> 00:02:22.400
Michelle, thanks for hopping on.
00:02:22.719 --> 00:02:23.199
Thank you.
00:02:23.439 --> 00:02:24.560
Happy to join.
00:02:24.960 --> 00:02:33.759
So, Michelle, before we jump into our topic, can you give us uh a background about yourself, how you got into research in the first place, and and uh what you're doing now?
00:02:34.319 --> 00:02:34.879
True.
00:02:35.439 --> 00:02:45.039
I think, and you may hear this on uh your podcast quite often, but I think like many others, I sort of fell into the idea of clinical research as a career.
00:02:45.280 --> 00:02:45.520
Yes.
00:02:45.840 --> 00:02:51.280
Uh I was enlightened by the potential of it.
00:02:51.360 --> 00:03:05.520
Whenever I was a senior in my undergrad, I took a research applications course and really enjoyed the class and just the idea of conducting research.
00:03:05.599 --> 00:03:10.400
It was and it was focused on clinical research and the applications of it.
00:03:10.719 --> 00:03:16.400
And my professor happened to be someone who had a health and developmental genetics lab.
00:03:16.560 --> 00:03:26.479
And because the course was interesting to me, I ended up asking him if I could do a work study for a semester in his lab.
00:03:26.639 --> 00:03:32.639
So I did that and got to, you know, just kind of experience being part of some projects.
00:03:32.960 --> 00:03:38.000
And then after I graduated, well, well, let me back up a step.
00:03:38.080 --> 00:03:40.879
I actually changed my major then related to that.
00:03:41.039 --> 00:03:51.919
It was initially a nursing major when I was in college, and then loved the idea of working in the medical field, but I also really like science.
00:03:52.080 --> 00:04:10.960
And so I think the piece of the work that was missing a little bit for me from a nursing aspect, I suddenly realized was possible in work when it came to working with research that touched humans and and and our healthcare and and things that we face all the time.
00:04:11.120 --> 00:04:16.000
So I think that you know that it was really a kind of a pivotal moment for me personally.
00:04:16.160 --> 00:04:20.240
So after I graduated, I ended up working for that professor.
00:04:20.399 --> 00:04:27.279
It was just a part-time job, but I stayed there for maybe six or eight months, just again, getting some more experience.
00:04:27.439 --> 00:04:34.959
And then ultimately I ended up uh starting to look for positions in clinical research.
00:04:35.040 --> 00:04:38.079
And I ended up becoming a clinical research coordinator.
00:04:38.319 --> 00:04:44.879
My first role was at Neo Clinic, and I and my first role was in oncology uh clinical research.
00:04:45.120 --> 00:04:50.720
And that was um, I don't know if I want to use the years here.
00:04:52.160 --> 00:04:53.360
You don't have to.
00:04:53.600 --> 00:04:53.920
Okay.
00:04:55.199 --> 00:05:01.360
So so after that, so I spent several years working on oncology clinical trials as a coordinator.
00:05:01.600 --> 00:05:04.720
Uh ultimately ended up specializing just a
Load full transcript
little bit.
00:05:04.879 --> 00:05:08.959
I transitioned to more of a program manager type of role.
00:05:09.040 --> 00:05:13.519
Uh, I started working for one PI who was a cancer epidemiologist.
00:05:13.759 --> 00:05:17.519
And so he hired me specifically to work with his program.
00:05:17.680 --> 00:05:20.240
Again, I was still within Mayo there.
00:05:20.399 --> 00:05:22.319
And then that sort of snowballed work.
00:05:22.639 --> 00:05:39.600
So essentially, I was a coordinator at Mayo for a total of we can code the years here, 2004, eight years, uh, kind of taking on additional responsibilities in that coordinator role during that time.
00:05:39.680 --> 00:05:46.240
So kind of moving from just managing the projects to more of understanding some of the contracting aspects.
00:05:46.399 --> 00:05:51.360
And at the time when I was a coordinator, I also did the regulatory work, budget development.
00:05:51.600 --> 00:06:01.199
Move on to I was very fortunate to work with PIs who gave me opportunity to participate in publications and meeting presentations and things like that.
00:06:01.519 --> 00:06:06.800
And after that, I moved into a supervisory role at Mayo.
00:06:06.959 --> 00:06:10.800
So that kind of started my stint in uh management.
00:06:11.040 --> 00:06:25.360
And so I managed there for a few years before, again, in the Cancer Clinical Trials office, but I actually had a dual manager role with other coordinators working on more population-based projects like I was.
00:06:25.519 --> 00:06:29.040
Um, so more translational registry-focused work.
00:06:29.439 --> 00:06:42.959
And then ultimately I ended up, for personal reasons, relocating to Kentucky and working there for Markey Cancer Center and their quality assurance office.
00:06:43.120 --> 00:06:52.959
There, I first was in monitoring and auditing, and then in education, those things kind of naturally fit together, of course.
00:06:53.199 --> 00:06:59.839
Not only the materials for onboarding of new staff, but things you identify for continuing education opportunities.
00:07:00.000 --> 00:07:02.800
You might see those, you know, when you're monitoring and auditing.
00:07:02.879 --> 00:07:06.000
So was all part of their quality assurance program.
00:07:06.399 --> 00:07:14.879
Uh, until finally I came to my role here with University of Cincinnati Cancer Center and uh as the director.
00:07:15.040 --> 00:07:26.399
And so now I have a role in overseeing really all the the operations of our office, including those quality assurance components and things like that.
00:07:26.560 --> 00:07:37.839
So it's been really great to have sort of all the background experience and understand a little bit about the roles of the people that I work with on our team every day.
00:07:37.920 --> 00:07:38.639
So yeah.
00:07:38.800 --> 00:07:39.680
No, that's awesome.
00:07:39.759 --> 00:07:40.000
Thank you.
00:07:40.079 --> 00:07:40.720
Thank you for sharing.
00:07:40.879 --> 00:07:52.319
So, and I I want to
just to lay it out for everybody listening, I I want to talk to you about your role specifically as the the director there in the cancer center at UC.
00:07:53.040 --> 00:07:58.000
I mean, you have sort of the the administrative leadership job running this sort of program there.
00:07:58.160 --> 00:08:06.000
I want to talk about what that looks like, not just at a uh an independent site, but you are at an academic medical center at a cancer center, right?
00:08:06.079 --> 00:08:19.839
So I know this is is very sort of uh niche, but you know, obviously there's a lot that goes into the administrative side of research that if you're just not in that world, you just don't have any visibility into it.
00:08:19.920 --> 00:08:30.560
I I guess I'm curious, hearing how you got into this and started out as a coordinator, did you always have the sort of interest of going into management slash leadership business stuff?
00:08:30.639 --> 00:08:33.919
Or was it what did that just happen because the opportunities came up?
00:08:34.159 --> 00:08:34.879
I really didn't.
00:08:35.039 --> 00:08:38.720
I think it happened because the when the opportunities came up.
00:08:38.799 --> 00:08:57.120
I I would I will say this in in my roles as a coordinator, as they progressed over time, I was often involved in sort of building maybe the infrastructure to execute a larger research study, for example.
00:08:57.360 --> 00:09:03.679
Okay, or the components that were really going to sort of set this project up for success.
00:09:03.759 --> 00:09:11.200
And so then I think one of the things that I recognize is that I like being part of building.
00:09:11.519 --> 00:09:23.200
And, you know, what I really have found rewarding about working in research throughout my career is really that I'm contributing to improving the care of people, right?
00:09:23.360 --> 00:09:30.879
There is something that about the work that I view it as more an act of service, right?
00:09:30.960 --> 00:09:32.799
I want to help others.
00:09:33.039 --> 00:10:02.480
And so I think even though my my role now is a step removed from interacting with our research participants or patients in the healthcare setting every day, I know that if I can build the right framework to successfully and conduct quality research, then I still feel that I have this contribution overall to the next generation.
00:10:02.879 --> 00:10:03.440
Absolutely.
00:10:03.600 --> 00:10:04.080
I love that.
00:10:04.159 --> 00:10:04.480
I love that.
00:10:04.559 --> 00:10:08.559
No, I think I think you you obviously do that as the the job, it sounds like, right?
00:10:08.720 --> 00:10:17.519
Is to build and and maintain or whatever that that sort of infrastructure, like you said, so that these studies can run there successfully, patients can enroll in them.
00:10:17.600 --> 00:10:25.600
Like that's that's awesome that you're that A, that you recognize that it is sort of a step removed, but also that you understand the the connecting points, right?
00:10:25.679 --> 00:10:52.559
Like how your work and that I again, research is so siloed, even within an organization, but especially when you look back at like what uh a pharmaceutical company, a sponsor does versus a CRO versus a site, like everyone does their own thing and they don't really have a lot of visibility into each other's worlds, so yeah, understanding how you connect to the the actual purpose, because honestly, that's why everybody should be doing this in research, right?
00:10:52.639 --> 00:10:58.399
Like you you have to figure out how you connect back to the patient because you know, I guess why else would you be in this industry?
00:10:58.559 --> 00:11:04.399
Um but I I do want to so you mentioned the the sort of infrastructure framework.
00:11:04.559 --> 00:11:08.960
Can you help us understand what that looks like?
00:11:09.120 --> 00:11:14.960
If you could sort of bucket out, I'm just saying, I'm thinking about a cancer center, right, that does research.
00:11:15.120 --> 00:11:16.720
There, there's a lot going on.
00:11:17.039 --> 00:11:20.799
In your role, what does that framework look like?
00:11:20.960 --> 00:11:21.759
What are the functions?
00:11:21.919 --> 00:11:28.480
What are the either the operational functions or the the uh tasks that you know people that you're in charge of?
00:11:28.639 --> 00:11:30.240
Like how does that break down?
00:11:31.200 --> 00:11:35.679
Well, I can just kind of talk through a little bit of about our office structure.
00:11:35.840 --> 00:11:46.879
I think in a lot of ways we look similar to other cancer clinical trials office, but um, so just touching on some of the elements that fall within our team.
00:11:47.039 --> 00:11:50.240
We do have, of course, all of the regulatory components.
00:11:50.559 --> 00:12:04.960
But for for us, I have distinct, I have a distinct team that focuses on uh not only the regulatory pieces of trial activation, but then the regulatory aspects of regular maintenance.
00:12:05.120 --> 00:12:13.840
So once a study is open to accrual through the time of closure, we have what I would call our clinical research coordinator teams.
00:12:14.000 --> 00:12:24.080
They're made up of our staff that are interacting with the potential research participants and research participants throughout their time on the study.
00:12:24.639 --> 00:12:35.919
We have also staff that are focused uh within those teams, staff that are focused on the data entry piece of the work and also participant follow-up.
00:12:36.320 --> 00:12:44.879
So once someone has completed their active protocol therapy, you know, we may be following them as part of the study.
00:12:45.120 --> 00:12:55.600
Gosh, if we're following them for survival, it can be upwards of 20 years sometimes that we are just routinely touching base with them.
00:12:55.840 --> 00:12:59.759
And then we also have a quality assurance component.
00:12:59.919 --> 00:13:03.360
So we have a QA program as part of our office.
00:13:03.600 --> 00:13:09.600
They do a lot of work not only with our investigator-initiated studies.
00:13:09.840 --> 00:13:17.360
So I'll kind of once I talk about roles, maybe skip to kind of the different types of studies that we support and why that's relevant.
00:13:17.440 --> 00:13:32.399
But yeah, the QA program does a lot to support our investigator-initiated studies, not only from the development side, but also once that study is open, the ongoing monitoring and auditing.
00:13:32.639 --> 00:13:52.000
So depending on the threshold, if it is a study where we, our physician or PI is the sponsor investigator, then we are conducting maybe monitoring visits at other locations, things like that, much like someone familiar with sponsors or CROs recognize that they're doing.
00:13:52.240 --> 00:13:59.120
And then in addition to that, as part of QA, we have our own internal auditing mechanisms and our education.
00:13:59.200 --> 00:14:04.559
So again, back to kind of onboarding and training, and then our continuing ed.
00:14:04.799 --> 00:14:20.879
So things that either we identify through regulations changes, just ongoing process changes which happen all the time, or as we kind of process improve ourselves, yeah, our workflows, which is definitely something that's ongoing.
00:14:21.120 --> 00:14:30.559
So I think again, like I said, we look pretty similar to other cancer centers and kind of distinguishing the functions within the office in that way.
00:14:30.799 --> 00:14:34.399
It enables us to have a lot of cross-coverage.
00:14:34.639 --> 00:14:44.240
I think one of the components of the studies that we support now is they're not all going to enroll a lot of participants.
00:14:44.720 --> 00:14:49.120
You know, we're now we're in a time of targeted therapies.
00:14:49.519 --> 00:14:58.080
And from that perspective, we may have fewer patients that qualify for some of the trials that we run.
00:14:58.240 --> 00:14:58.320
Right.
00:14:58.559 --> 00:15:08.720
But at the same time, the potential of the treatment offering some benefit to that participant who does qualify, it's important that you have that available to them.
00:15:08.879 --> 00:15:12.559
Our physicians feel that that's important for their potential care.
00:15:12.799 --> 00:15:20.960
So with that, we have a multitude of studies that are open at any given time.
00:15:21.039 --> 00:15:36.159
But again, just recognizing that some of the days of having studies that are going to enroll, let's say, you know, 20 to 30 patients at our site are less likely now.
00:15:36.399 --> 00:15:51.679
And so with that, we have maybe more protocols, but we also have the ability within our staff and teams and the functions that our team can cross-cover each other so that we don't have one expert on a protocol.
00:15:51.840 --> 00:15:53.519
We we may have three, you know.
00:15:53.759 --> 00:15:54.480
Oh, interesting.
00:15:54.799 --> 00:16:00.879
So it helps to support the ongoing kind of ebb and flow of movement on a given study.
00:16:01.279 --> 00:16:01.840
Interesting.
00:16:02.000 --> 00:16:02.559
That's interesting.
00:16:02.720 --> 00:16:20.320
Well, and that that actually, just thinking through what you're talking about, and and I know that this is uh an oncology thing that you're talking about, I guess, that that you're seeing in research that that you're seeing more uh targeted therapies and so less people in each study, maybe more protocols, like you said, but less enrolled participants.
00:16:20.399 --> 00:16:31.919
Uh how does the and and how do you guys manage um I guess your department budgets with say sponsors for studies, how has that impacted that?
00:16:32.080 --> 00:16:42.399
Because I feel like, you know, if the traditional model is you enroll as many people, and the more people you enroll, the more money you make, kind of thing, how has that impacted you guys?
00:16:42.879 --> 00:16:48.799
Well, I think interestingly enough, we so a couple of comments about that.
00:16:49.039 --> 00:17:04.079
One, from an industry perspective, I mean, very often, again, it's not out of the question from a feasibility perspective to be saying, you know, we think we may have five potential participants that can enroll at our institution to this study.
00:17:04.480 --> 00:17:12.400
And so, you know, maybe overall nationally the trial is targeting 120, but it's five of them potentially could be from our side.
00:17:12.640 --> 00:17:19.920
And from a feasibility perspective, that's a reasonable expectations from the sponsor side as well, right?
00:17:20.160 --> 00:17:20.319
Sure.
00:17:20.559 --> 00:17:21.200
But I think so.
00:17:21.279 --> 00:17:36.480
I think what ends up happening with that is we are looking more at our portfolio overall than we are at a specific trial and the number of patients.
00:17:36.720 --> 00:17:41.599
We want to make sure that it's worth the resources to open the study.
00:17:41.759 --> 00:18:04.720
So we do a review to understand do patients with this diagnosis kind of to the level that we can with that pre-screening waiver review that we or approval that we have in place with IRB to say where we look at feasibility to say, do we have participants available for this study that could be candidates?
00:18:04.880 --> 00:18:06.160
You know, yes or no.
00:18:06.319 --> 00:18:06.480
Yeah.
00:18:06.640 --> 00:18:10.799
But beyond that, we approach that in terms of portfolio balance, like I mentioned.
00:18:11.039 --> 00:18:22.559
So across cancer types, we are looking to see, okay, for this type of cancer, do we have something available for newly diagnosed participants?
00:18:22.799 --> 00:18:31.039
Do we have something available for individuals who maybe have have not responded to their first line of therapy?
00:18:31.599 --> 00:18:35.279
Maybe now they're moving on to their second or onto their third.
00:18:35.440 --> 00:18:56.880
And then, and so we want to ensure that kind of no matter what phase or situation that
that individual is in in terms of their care, that there may be a study that offers some alternative therapy for them to what we would call the standard of care.
00:18:57.279 --> 00:19:04.640
And so that's how our physicians review the study for portfolios within their programs.
00:19:05.200 --> 00:19:13.599
So what do you sorry, what when you talk about the physicians reviewing studies for the portfolio, what what is that process?
00:19:14.079 --> 00:19:30.319
Yeah, so we actually have what we call disease research group meetings, um, where our faculty, physicians, nurse practitioners, members of our study team uh are present at the meeting, they review studies that are open.
00:19:30.559 --> 00:19:36.400
And we actually we make what's called a trial tree, but it essentially is just what I mentioned.
00:19:36.559 --> 00:19:59.519
So, kind of for all of the different clinical scenarios that a patient could be in at that time, do we have some type of study that can address that possible need for someone again, providing that potential alternative route for therapy if they're if they're a candidate?
00:19:59.759 --> 00:20:09.839
Because at the end of the day, not all participants can qualify for a clinical trial, but also the standard of care, they always be available, right?
00:20:10.000 --> 00:20:31.359
So if at that unique time the trial is the best option, both from the participants' perspective and the physician's perspective, and they agree they want to move forward with that study, then they may have the standard of care to go to as their next line of treatment if it wasn't effective.
00:20:31.759 --> 00:20:32.480
Yeah, no, thank you.
00:20:32.559 --> 00:20:40.160
And and I mean this makes sense again, thinking of since in and I mean when you think about all therapeutic areas of research that that could happen, right?
00:20:40.400 --> 00:20:43.119
Oncology is obviously the closest to clinical care, right?
00:20:43.200 --> 00:20:45.039
Because it's sort of an extension, right?
00:20:45.119 --> 00:20:47.759
Research is sort of an extension of their clinical care in your world.
00:20:48.160 --> 00:20:49.920
Yes, it's very intertwined.
00:20:50.319 --> 00:20:51.440
Yeah, yeah, for sure.
00:20:51.599 --> 00:21:06.160
And I and I think that that's helpful to understand too, because okay, so and and you know, you kind of mentioned the budget stuff a little bit about how you guys see the feasibility and whatnot, and you have to make sure that it makes sense to bring on a trial, of course, financially, because you're paying people and all that stuff.
00:21:06.400 --> 00:21:10.559
But as a program, you're talking about a portfolio.
00:21:10.640 --> 00:21:19.519
It sounds like how you measure success is not necessarily revenue, straight revenue coming in from clinical trials, right?
00:21:19.759 --> 00:21:20.079
Yes.
00:21:20.319 --> 00:21:28.240
So tying all of that kind of back together, and where I was going with kind of at, you know, evaluating things at the program level, yeah.
00:21:28.400 --> 00:21:36.079
We really do measure success by having those alternatives available for for people.
00:21:36.720 --> 00:21:42.799
We actually we don't financially benefit from conducting trials.
00:21:43.039 --> 00:21:46.160
We have we have tools in place as an institution.
00:21:46.319 --> 00:21:55.599
And one of the reasons why I really enjoy working at an academic medical center is we have, as I mentioned earlier, investigator initiated studies.
00:21:55.759 --> 00:21:59.759
So studies that have been written by our physicians and faculty members.
00:22:00.319 --> 00:22:04.559
That you know ultimately re uh develop and operationalize.
00:22:04.720 --> 00:22:12.240
And some of those do have maybe some financial support because they have an extramural grant or something like that.
00:22:12.559 --> 00:22:21.519
The other expectation is that we also conduct what I call uh cooperative group studies, but there are studies that are funded through the National Cancer Institute.
00:22:21.759 --> 00:22:37.599
They are typically larger, maybe late phase two or phase three studies for the most part, where the the budget is really just a very minimal payment to support the enrollment in and of itself.
00:22:37.759 --> 00:22:45.359
But again, we actually just look for uh a zero balance across all of the elements.
00:22:45.440 --> 00:22:51.200
So can we support the work that we're doing and the people that we need to do it from a quality perspective?
00:22:51.359 --> 00:22:51.519
Yeah.
00:22:51.759 --> 00:22:54.799
Um, you know, and a and a compliance perspective.
00:22:55.119 --> 00:22:59.519
And are we uh do we have adequate resources basically?
00:22:59.680 --> 00:23:09.279
And then beyond that, we're not necessarily looking to generate revenue above and beyond that in continuing our network.
00:23:09.680 --> 00:23:15.200
No, I think and that again, that makes sense, especially at an academic medical center, like you're saying.
00:23:15.440 --> 00:23:34.400
I guess, but it still sounds like it would be difficult, even if you're talking about a zero, you know, zeroing out your your your budget, it would be difficult to if you have a portfolio and the the sort of directives are you have to have available studies as much as possible, right?
00:23:34.640 --> 00:23:45.359
For all of these different indications or different phases of of cancer care and everything for your patients, at some point you might not be able to, I would imagine you wouldn't be able to balance it.
00:23:45.440 --> 00:23:48.319
You still like you have to have resources for these things.
00:23:48.400 --> 00:24:02.640
And I imagine even in you talk about cooperative groups and NCI gives some funding, but then the investigator initiated, if they don't have uh, you know, other funding coming in, I imagine there are some that are unfunded, like completely.
00:24:02.880 --> 00:24:12.799
Yeah, I would say the proportion of studies we can afford to
do that truly have no funding whatsoever, it's going to be pretty limited.
00:24:13.039 --> 00:24:13.200
True.
00:24:13.599 --> 00:24:18.720
We have there are some maybe internal mechanisms for pilot awards.
00:24:19.039 --> 00:24:29.200
We also have um investigators who have partnered with industry sponsors who maybe are providing drug or drug and some funding in support of their project.
00:24:29.440 --> 00:24:41.200
Many of them have avenues at which physicians can propose studies to them that they then review and approve, very similar to kind of other grant mechanisms, for example.
00:24:41.440 --> 00:24:53.119
And so a lot of the IITs that I say IITs, that's investigator-initiated trials, but a lot of the studies that we would manage, they do have some support in that way.
00:24:53.279 --> 00:24:54.720
And it's really quite necessary.
00:24:54.799 --> 00:24:58.000
And I think that's one of the biggest hurdles for our physicians.
00:24:58.240 --> 00:25:12.400
And the other area where I see continued opportunity and and value in this is I want to be able to support our physicians and and their and their ideas for studies.
00:25:12.480 --> 00:25:18.799
I think because they know what they see and experience in their clinics with their patients every day.
00:25:18.960 --> 00:25:27.359
And so a lot of times their ideas are sort of born from the things, the challenges that they see while they're administering that care.
00:25:27.440 --> 00:25:31.039
And I think that you know it's important to help facilitate.
00:25:31.279 --> 00:25:39.680
And I know that's a big hurdle for them is to find a funding source a lot of times when they do have that idea for a trial.
00:25:39.839 --> 00:25:48.079
And so we try to support them in one, identifying what those potential opportunities could be.
00:25:48.319 --> 00:26:10.079
I know through our cancer center now, as we've grown, that we've actually developed kind of regular routine communications to the faculty with the RFAs that are open right now through various external organizations, what our internal funding opportunities might be if there are grant funds.
00:26:10.319 --> 00:26:36.319
And then from physicians and mentoring each other as in their research careers as they grow, they also will help to introduce them to company contacts and things like that, so that when they do want to learn more about the potential to uh actually operationalize their trial, they have those sources that you know they can go to and and ask, you know.
00:26:36.640 --> 00:26:38.960
Yeah, that's super helpful, I'm sure.
00:26:39.279 --> 00:26:54.480
And it's it sounds like it's a real sort of partnership with the physicians between your what your uh role and function is as a as a sort of uh you know, research administrative support, uh operation support, uh running the trials.
00:26:54.799 --> 00:27:00.240
I might I was thinking as you're talking about the physicians and and them bringing studies to you sometimes.
00:27:00.400 --> 00:27:03.119
What how do you bring in in general?
00:27:03.200 --> 00:27:06.640
How do you bring in studies besides investigators having their own ideas?
00:27:06.799 --> 00:27:14.079
What what is the mechanism that you guys use to either attract pharma studies or you know, how does that part work?
00:27:14.480 --> 00:27:29.119
Well, um, so again, kind of depending on the the sponsor of the study, but if it's a pharmaceutical company, we have at this point we have established relationships with CROs and companies.
00:27:29.359 --> 00:27:31.839
So we are often contacted by them.
00:27:32.079 --> 00:27:41.119
And it may be a direct contact to a member of our team because they again, we have a a team that's very focused on trial activation.
00:27:41.440 --> 00:27:56.319
So sponsors or CROs have the their names and contact information, may just be reaching out to them versus reaching out to the physician directly, or sometimes they reach out to the physician and the physician will then send it to us.
00:27:56.480 --> 00:28:06.160
And then if it's some of those national studies, we're essentially notified at the group level, just well, when a new study is activated.
00:28:06.559 --> 00:28:17.519
But our team will actually go, there's a central portal for those, and our team will go and essentially look at all new study opportunities within a certain cancer disease area.
00:28:17.680 --> 00:28:24.559
So let's just pick one and say within lung cancer, and they'll say, okay, well, are do we have any new studies in lung cancer?
00:28:24.640 --> 00:28:34.640
And then at that disease research group meeting that I was um mentioning, they will discuss the new opportunities, no matter what the sponsor's source is.
00:28:34.960 --> 00:28:45.279
So it could be a again, a pharmaceutical company, one of those NCI-sponsored studies, um, an internal project, and they're they'll discuss it at that time.
00:28:45.519 --> 00:28:51.519
And then essentially our teams will decide if yes, we think this is a great fit.
00:28:51.680 --> 00:28:54.160
We have the patients for this study.
00:28:54.319 --> 00:28:59.119
We don't have a study that's going to compete with it for enrollment, things like that.
00:28:59.200 --> 00:29:04.480
Um, so they'll they'll essentially vet all the projects within the group at that time.
00:29:05.039 --> 00:29:19.519
So, okay, so then that that committee you were talking about with the physicians, they all the study, the potential studies go to them, they say what they like, then it gets kicked to you guys to do feasibility, or do you are you doing feasibility before and providing that at that committee meeting?
00:29:19.920 --> 00:29:34.160
Once the physician we ask the physicians to confirm that they indeed want to move forward with it as an opportunity before we do the next step with let's say that full feasibility questionnaire.
00:29:34.480 --> 00:29:45.519
And then it will once they've essentially voted yes, then you know, we'll move it
into the activation pipeline from there and just move it forward.
00:29:45.839 --> 00:29:52.079
So then what uh you had mentioned like there are obviously reasons why they may say no, they're not interested, or they don't, you know, think you could do it.
00:29:52.240 --> 00:29:55.359
I think you had mentioned uh like competitive enrollment stuff.
00:29:55.440 --> 00:29:57.519
What what is what does that mean?
00:29:57.599 --> 00:30:02.000
And just so people understand, like how yeah, how does that happen?
00:30:02.480 --> 00:30:06.720
Yeah, so well, I think I had mentioned therapies being targeted.
00:30:06.880 --> 00:30:14.319
Sometimes there may be studies that really are they compete with each other because of their eligibility criteria.
00:30:14.400 --> 00:30:23.359
So maybe it's for newly diagnosed haggers cancer patients with uh with X mutation, something like that.
00:30:23.599 --> 00:30:27.359
But we do evaluate the eligibility criteria.
00:30:27.519 --> 00:30:29.119
We'll ask for a synopsis.
00:30:29.440 --> 00:30:37.519
If it is an externally sponsored study, like say from a pharmaceutical company, we request a synopsis, and that's what the physicians are reviewing.
00:30:37.599 --> 00:30:47.440
So we can take a more detailed look to again, it's it's that first look at feasibility before doing that more detailed questionnaire submission, for example.
00:30:47.680 --> 00:30:50.000
But we are evaluating it then.
00:30:50.240 --> 00:30:57.440
Do we have a study open now that may be complete with the enrollment period by the time this study is open to accrual?
00:30:57.519 --> 00:31:00.319
If so, you know, there's no no competition.
00:31:00.559 --> 00:31:10.720
If there are similar therapy for or maybe similar in eligibility in some way, what's the rationale for having more than one study open in that area?
00:31:10.880 --> 00:31:11.759
And they do exist.
00:31:11.920 --> 00:31:13.759
Maybe there's something nuanced.
00:31:13.839 --> 00:31:22.960
Well, this one is for participants who had to have received uh prior treatment with uh plat or something like that.
00:31:23.200 --> 00:31:24.240
I'm just throwing out examples.
00:31:25.759 --> 00:31:33.839
So from that, you can get a little bit more nuanced and say, so actually, this won't be an issue of enrollment with the same patient population.
00:31:34.240 --> 00:31:34.480
Yeah.
00:31:35.119 --> 00:31:46.720
That gosh, I mean, everything that you're talking about, I nuanced is the perfect word because not only are you, I mean, you you have a very mission-driven, you know, setup there, right?
00:31:46.880 --> 00:32:06.480
Like with the the whole portfolio and the the goals with that, and then you have anytime you're doing feasibility for research, and this is just a blanket statement across the board for any research site, uh trying to identify how many people might we, you know, do we think we might enroll in a study like this, given the protocol, given the limited information you have, all that stuff.
00:32:06.880 --> 00:32:10.480
And then and then the competitive enrollment adds that other layer, obviously.
00:32:10.559 --> 00:32:12.559
That's like, where is that line?
00:32:12.799 --> 00:32:20.559
Like, there's not, there's not gonna be, I probably there's not gonna be many protocols that have the exact same inclusion, exclusion, right?
00:32:20.640 --> 00:32:44.720
They're not gonna be verbatim necessarily, but to your point, you have somebody has to assess this is either close enough that it doesn't make sense, we don't want to step on our toes to try to enroll in both, versus, like you said, maybe there's something slightly different that, but then at that point, you know, if it's slightly different, then you're still left with the problem of you come across, say, one patient that could be eligible for both.
00:32:45.039 --> 00:32:47.119
Do you push them into one direction or the other?
00:32:47.279 --> 00:32:48.160
Do you give them the option?
00:32:48.319 --> 00:32:50.640
Like that's a just a lot of nuance there.
00:32:50.960 --> 00:33:00.079
There is, and I would say normally they're presented with the option, again, recognizing that each study also has requirements of the participants.
00:33:00.240 --> 00:33:02.319
How often are you asking them to come in?
00:33:02.400 --> 00:33:07.519
You know, what are what are sort of the the maybe the extra things that they're going to need to do?
00:33:07.680 --> 00:33:17.119
So, you know, that at that point they have the they can decide what they might think would be the best fit for them and that they would like to move forward with.
00:33:17.279 --> 00:33:29.519
And then ultimately in that case, if they for some reason were a screen failure for that maybe first first choice, and then maybe you know, then everyone collectively decides to move to a second.
00:33:29.759 --> 00:33:35.279
But to your point, I think the other aspect of all of this is not just opening.
00:33:35.440 --> 00:33:40.480
We we try to be good stewards in opening the right studies, right?
00:33:40.640 --> 00:33:58.079
So ensuring that you are opening protocols where again you there are there is a need, not only within your portfolio, but that you have the population available, you have the resources available to do it because of whatever the maybe that study's requirements are.
00:33:58.640 --> 00:34:05.119
But beyond that, once a study is open, we do evaluate each in an ongoing way.
00:34:05.279 --> 00:34:13.039
So every six months within our office, every study, so both at the beginning and then in an ongoing way.
00:34:13.199 --> 00:34:15.360
Every study receives a scientific review.
00:34:15.519 --> 00:34:23.599
But the scientific review committee, the ongoing mission is to evaluate how they're performing from an accrual perspective.
00:34:23.840 --> 00:34:27.199
So are we meeting our accrual goals for this?
00:34:27.440 --> 00:34:30.880
If not, is there a specific reason why?
00:34:31.119 -->
00:34:38.800
Or is this a very rare population where maybe it's just going to take an extended period of time to meet its goals?
00:34:38.960 --> 00:34:44.639
And the idea of that is just again, are we being good stewards of the resources?
00:34:44.800 --> 00:35:03.440
So ultimately, if we have a study open that no participant is able to enroll in, well, then we may want to consider closure of that protocol so that we can have the opportunity for something new to come in that is something that is better to have available for participants.
00:35:03.920 --> 00:35:06.079
No, that's actually nice to hear.
00:35:06.320 --> 00:35:12.559
I think just in general, for people to understand that that's an ongoing um thing that you guys do, right?
00:35:12.639 --> 00:35:17.679
That you're constantly looking at stuff, because I know that that's obviously a problem in research in general.
00:35:17.840 --> 00:35:25.199
A lot of sites will open up studies thinking that they can enroll patients, and it and then they they don't end up enrolling and they just keep it open forever.
00:35:25.360 --> 00:35:29.599
And and that's just obviously you're just you know digging the hole deeper.
00:35:29.760 --> 00:35:32.239
But again, all of that stuff takes resources, right?
00:35:32.320 --> 00:35:39.039
Like all of that takes time, energy, people to do that assessment to regularly check back in with the studies.
00:35:39.199 --> 00:35:44.159
Like that's a lot of so tracking metrics, all of that, yes.
00:35:44.559 --> 00:35:45.280
Yes, yes.
00:35:45.440 --> 00:35:55.599
So then I guess from that side of it, what what do you I mean we people talk all the time about the the sort of burden of technology at the site level?
00:35:55.760 --> 00:36:01.119
I mean, I imagine you guys have quite a few systems, you know, that you're using.
00:36:01.280 --> 00:36:07.599
And I assume that you have systems that sort of live within your cancer center there for for your research program.
00:36:07.840 --> 00:36:08.960
Uh what does that look like?
00:36:09.039 --> 00:36:11.519
What is your what do your technology solutions look like?
00:36:12.480 --> 00:36:24.079
So we do use e-regulatory, that's 21 CFR Part 11 compliant, so we can facilitate electronic signatures, which I think is definitely a very helpful tool.
00:36:24.320 --> 00:36:28.000
And then uh we also use a clinical trials management system.
00:36:28.559 --> 00:36:50.400
So from my standpoint, that's just a must-have across hundreds of um studies looking at timelines, enrollments, screening, and and and enrollment information, those kind of things, and being able to pull reports at uh as I mentioned, like I can pull reports to look at a specific program.
00:36:50.559 --> 00:37:01.920
So let's say I wanted to see all of the studies we had open in breast cancer and for how long they've been open and what the accrual was and those kind of things.
00:37:02.159 --> 00:37:03.840
I can do that at any point.
00:37:03.920 --> 00:37:13.679
And I think for me and all of our teams, honestly, just something that's very necessary, not to mention kind of the components that go along with just having a study open.
00:37:13.840 --> 00:37:16.639
You need to have means of notification.
00:37:16.800 --> 00:37:23.760
So when studies are amended and there are new requirements or new consent forms and you know, just things.
00:37:23.920 --> 00:37:54.480
I think having some of these tech tools, as you mentioned, is very critical because we're really able to use them for these purposes, ensuring we're getting the right information to the right people at the right time, that we have a reference for when we activated that amendment from a regulatory standpoint, for example, that we can track who, you know, if there were five participants, that three of the five have reconsented and two are left.
00:37:54.559 --> 00:37:57.920
And that kind of thing, again, across the whole portfolio.
00:37:58.159 --> 00:38:07.199
I think the the technology certainly helps with them, the tracking of these unique needs, and then also, like I said, the ongoing metrics of them.
00:38:07.519 --> 00:38:09.440
Yeah, I mean, it sounds like that's absolutely necessary.
00:38:09.519 --> 00:38:14.159
You wouldn't be able to to do it at scale like you're doing without those tools.
00:38:14.320 --> 00:38:41.119
And and I guess to to think about your uh world and and everything that you're sort of in in charge of there or leading or whatever, what is or it could be a couple things, what what are the the biggest challenges that you have in terms of making sure that the infrastructure, the resources, and everything else are in place to meet the goals and you know, and be successful as a cancer center?
00:38:42.320 --> 00:38:56.480
I think some of the biggest challenges are actually in operationalizing a study, not so much from our resources.
00:38:56.639 --> 00:39:12.400
I think you know, you have a great perspective on what you've built within your team, but we mentioned earlier on that our studies are very intertwined with the healthcare system and with patient care.
00:39:12.880 --> 00:39:33.920
And so it's just we're trying to do something that many times we're maybe asking for extra things as part of study conduct that are just difficult in an environment where clinics, hospitals are busy, and they don't have a lot of extra resources either.
00:39:34.400 --> 00:39:46.079
And so we want to make it kind of as as insert ourselves into the process without disturbing the process as much as we can, if that makes sense.
00:39:46.320 --> 00:39:46.800
It does.
00:39:46.960 --> 00:39:58.000
So we we have to we are there to ensure that these the protocol is followed to the best of our ability, that we're meeting all of the study requirements.
00:39:58.079 --> 00:40:08.880
And so there's extra communication tools that we have between maybe our coordinators and the infusion suite nurses, for example.
00:40:09.119 --> 00:40:36.639
And so all those kind of extra things are, but they're just necessary to be able to ensure that we can really address all those study requirements in a way that, like I said, doesn't disrupt necessarily that nurse's day to the best that we can, but we know we need, hey, we have to draw PK samples at 15 minutes, 30 minutes, 45 minutes, three hours, six hours, eight hours, those kind of things.
00:40:36.880 --> 00:40:43.360
And so a lot of our team's focus not only is on I mentioned process improvement.
00:40:43.440 --> 00:40:49.840
So we do process improve ourselves, but we actually have some methods within our own office that we do.
00:40:50.000 --> 00:41:02.079
We have a process improvement committee, and anyone on our staff, we can you can just submit via red cap if you have a need or you think, hey, we should take a look at this workflow that we wrote.
00:41:02.239 --> 00:41:04.719
Maybe it needs updated, that kind of thing.
00:41:04.960 --> 00:41:12.239
But we also spend time meeting with the clinical staff because we want to understand what is the best way to communicate with you?
00:41:12.400 --> 00:41:18.639
Is it within the treatment plan in Epic, or is it something that's going to come to you outside of Epic?
00:41:18.800 --> 00:41:28.000
Is a physical piece of paper more helpful for you to record this information, or would you rather chart on it like you do your other requirements?
00:41:28.159 --> 00:41:33.280
So those are all the things that we want to understand from the teams and get their feedback on.
00:41:33.519 --> 00:41:39.920
Because, like I said, we want to make it as easy for them to help us with the protocol compliance.
00:41:40.400 --> 00:41:45.039
Yeah, and document everything you need to document for a research study.
00:41:45.360 --> 00:41:45.679
Yes.
00:41:45.840 --> 00:41:58.239
Well, and and I think that that is a that's such an important topic in general for especially when you're talking about research in a in a clinical setting, and then in the oncology, you add that extra layer.
00:41:58.400 --> 00:42:05.920
But like incorporating research into the clinical care model is you know what I mean.
00:42:06.000 --> 00:42:11.679
It's and and I know that that sort of it's not a debate, but some people disagree about how close those should be.
00:42:11.840 --> 00:42:24.960
Uh, again, oncology is is is unique and different because you're still left with even in oncology, you're left with the situation of making sure that the research participants understand if they're in a research study, it's research.
00:42:25.199 --> 00:42:27.519
And if they're in clinical care, they're clinical care, right?
00:42:27.599 --> 00:42:43.920
Like even as, even when research is an extension of, meaning there's no other clinical option, so then it it gets sort of uh you know moved over to research in your world, having that bridge, like I guess the shorter that bridge is between you and clinical, the better for everybody.
00:42:44.239 -->
00:42:54.559
But then how do you I guess I'm I'm thinking out louder asking you at the same time, how do you make sure that they also understand that research is research?
00:42:54.639 --> 00:43:02.320
It's not a, you know, it's not something that their doctor says or should necessarily say this is going to work for you, right?
00:43:02.800 --> 00:43:05.840
Yes, that's a really great question.
00:43:06.000 --> 00:43:13.840
I think a lot of that does go back to the time of consent and then the concept of ongoing consent.
00:43:14.159 --> 00:43:28.239
I I think we have some pretty, I would say, distinct workflows around actually obtaining the consent and the time that our team members spend in reviewing it with the participants.
00:43:28.639 --> 00:43:47.280
We ensure the physicians are involved to talk about the treatment aspects of what what the drugs are, for example, and and what the potential side effects of them are and again how they may not benefit that participant.
00:43:47.519 --> 00:43:54.880
But our team also spends additional time going through when sometimes the consent forms are what 50 pages long.
00:43:55.519 --> 00:43:59.360
I I mean just reviewing them with the potential.
00:44:00.159 --> 00:44:19.199
Participants and then using teachback methods throughout the process to ensure that to the best of our ability that there is a level of understanding there that this is a study and that these are the the aspects that are the hypothesis of the study.
00:44:19.360 --> 00:44:22.079
This is what we don't know, this is what it's testing.
00:44:22.320 --> 00:44:22.639
Right.
00:44:22.800 --> 00:44:25.840
Um, this is how this is what's extra for you.
00:44:26.000 --> 00:44:32.159
Maybe you know they're being asked to complete an extra clinical procedure that they wouldn't have otherwise had.
00:44:32.239 --> 00:44:34.880
And so explaining what's extra for them.
00:44:35.119 --> 00:44:43.599
I think one of the most challenging aspects for everyone is when it comes to actually the the financials.
00:44:43.760 --> 00:44:51.519
So I think studies are very clear in explaining now on consent forms what is paid for by the study and what isn't.
00:44:51.840 --> 00:44:57.039
But we do get a lot, you know, still questions on those aspects.
00:44:57.679 --> 00:44:58.400
Questions from who?
00:44:59.280 --> 00:45:00.000
The participants.
00:45:00.400 --> 00:45:00.800
Okay, okay.
00:45:01.440 --> 00:45:10.079
You know, maybe they were just about the bills that they received from the hospital or something like that after the class.
00:45:10.400 --> 00:45:18.320
But ultimately, we there's there's always components of this that are, like I said, standard of care.
00:45:18.480 --> 00:45:23.519
And so kind of all of that is happening at the same time outside of the study.
00:45:23.679 --> 00:45:32.960
And so it gets a bit confusing and and and I know for the for the patients kind of trying to understand all of that information.
00:45:33.519 --> 00:45:39.519
So we have again do our best to go over what is paid for by the paid for by the protocol.
00:45:39.599 --> 00:45:47.280
And a lot of times just the fact that the treatment itself is covered can hopefully be a financial relief.
00:45:47.599 --> 00:46:11.519
But otherwise, I know that's uh something that's can we'll ultimately refer them over to the patient financial resources just because our research team talk about kind of working in the an environment, but not necessarily being involved or educated around all the components of someone's insurance and how things get built.
00:46:11.760 --> 00:46:16.719
You know, we're just referring them to the experts to go through the details with them.
00:46:16.960 --> 00:46:21.920
Yeah, in hopes we can help them resolve and just be available to answer any questions.
00:46:24.800 --> 00:46:28.400
So now and then I assume that I mean you said you meet with the clinical staff.
00:46:28.480 --> 00:46:35.920
I assume the patient financial services folks have at least some level of awareness and understanding of research, right?
00:46:36.000 --> 00:46:39.039
To be able to sort of talk to patients about both sides.
00:46:39.119 --> 00:46:46.559
Because that's you uh it that is that's a very difficult situation because I don't I don't know anybody that understands insurance.
00:46:46.639 --> 00:46:48.079
I I don't understand it, right?
00:46:48.159 --> 00:47:03.119
Like when it gets into hospital clinical care, um it feels like it's made up, but uh like understanding that side plus the research side, it is it's two worlds, it's complicated, and again, nuanced to get back to that word, but that'd be tough for the patient.
00:47:03.760 --> 00:47:25.280
They are aware, and and you know, many times because there is a standard of care component involved in our research studies, the studies consent and treatment plan and things like that are actually involved in the pre-certification process, just like maybe they would be for any routine care item.
00:47:25.519 --> 00:47:36.320
But I mean, our a copy of a signed consent form was provided to that participant's insurance company uh for review and and verification.
00:47:36.559 --> 00:47:37.519
So yeah.
00:47:39.199 --> 00:47:41.840
Yeah, no, that that that would be a challenge, like you said.
00:47:42.000 --> 00:47:55.519
And and again, the idea that, like from the onset, you guys are trying again, like you said with that committee, you're trying to have a portfolio that is in in true service to the patient and the patient populations that you have.
00:47:55.920 --> 00:48:06.000
Um I mean, the biggest, I would imagine it would be the biggest sort of frustration to on the other side of that, once these people are in studies, to have those kind of headaches, right?
00:48:06.079 --> 00:48:13.599
The the misunderstandings and like how do we make sure that they are fully informed of of how this works and what's going on?
00:48:13.920 --> 00:48:15.519
Yes, that's that's a lot.
00:48:16.559 --> 00:48:17.519
Yes, it is.
00:48:17.920 --> 00:48:24.880
So uh Michelle, this is this has been fantastic, and I really appreciate you kind of talking through uh your program and how this sort of all works.
00:48:24.960 --> 00:48:31.280
I think this is again a side of research that a lot of people don't have uh access to, obviously, if you don't work within it yourself.
00:48:31.360 --> 00:48:36.559
Uh you talked about what it means to be uh successful, right?
00:48:36.960 --> 00:48:39.760
At the beginning in sort of the portfolio and your mindset, I guess.
00:48:39.840 --> 00:48:44.320
But how do you how do you know that you are uh successful?
00:48:44.480 --> 00:48:45.280
Does that make sense?
00:48:45.840 --> 00:48:46.400
Yes.
00:48:46.719 --> 00:49:01.199
Well, I I would say if if you asked me about it in terms of metrics on paper, I you know, we do evaluate ourselves in an ongoing way based on two things.
00:49:01.440 --> 00:49:12.559
One, so we know the number of individuals that maybe come to our hospital, our healthcare system that have a cancer diagnosis.
00:49:12.800 --> 00:49:23.840
And either they've come here and they and were diagnosed with cancer here, or they came here for an you know, maybe a second opinion and then went on to receive some type of therapy here.
00:49:24.000 --> 00:49:42.719
And so ultimately we know one of the ways we know we are successful is because I can look directly at those numbers and say of the number of individuals that came here, did you know, were we successful in enrolling them to clinical trials?
00:49:42.880 --> 00:49:46.800
Meaning we had meaningful studies available for them in their care.
00:49:46.960 --> 00:49:47.199
Yeah.
00:49:47.440 --> 00:50:03.440
And so I can really point to those numbers in an ongoing basis and say, okay, did at least 15 to 20 percent of the individuals that came here receive some type of therapy or enroll or participate in a study?
00:50:03.679 --> 00:50:04.239
Yeah, okay.
00:50:04.480 --> 00:50:09.119
And then the the other way we evaluate that is honestly through our community.
00:50:09.360 --> 00:50:17.840
So individuals that live in our community area, how many of them come to the center, those kinds of things.
00:50:17.920 --> 00:50:32.159
So we're constantly looking at our ability to do community outreach, education, and engagement because we want people to know that they don't have to travel far to receive good care.
00:50:32.320 --> 00:50:42.559
They can, yeah, you know, we're right here in their backyard and we have these options available for them, not only from the treatment perspective, but we have studies about cancer screening and prevention.
00:50:42.639 --> 00:50:53.599
And then once they complete their treatment and they're now in what we would call survivorship, but maybe still experience some effects physically from from having had cancer at some point.
00:50:53.760 --> 00:50:57.039
And so were we able to reach them with our studies?
00:50:57.199 --> 00:51:03.519
Do we have are we when we ask them about their needs, are we addressing them through the research that we're doing?
00:51:03.679 --> 00:51:46.000
And so we have that open dialogue going in the in in an ongoing way, and so I think that's really kind of the the mission for the whole program is not only from the number of people coming in, which like I said, I can look at that on paper, but when we're talking with people in the community, I mean I've I've been to our we have a community advisory board, I've been to meet with them several times and try to keep that conversation ongoing, but just understanding what their specific needs are, what they hear from their neighbors, and you know, do they know that they can come right here to our cancer center to get the care that they need?
00:51:46.159 --> 00:51:51.119
And you know, that there's actually more than just to that medicine that we can help them with.
00:51:51.199 --> 00:51:52.000
So yeah.
00:51:52.159 --> 00:51:53.039
Oh, that's fantastic.
00:51:53.119 --> 00:52:05.360
Well, I love it because again, this is obviously a very mission-driven program that you have, and and talking about your metrics and how you measure success, it sounds like you are a hundred percent targeting the patients and what what they need.
00:52:05.440 --> 00:52:09.199
I mean, it makes perfect sense, but it's also just nice to hear that spelled out.
00:52:09.360 --> 00:52:10.079
You know what I mean?
00:52:10.320 --> 00:52:14.480
Yeah, like this is why this is why these programs should exist, right?
00:52:14.719 --> 00:52:28.880
And and however they come in from your studies, whether they're investigator initiated or from sponsors or the cooperative groups, like you're focused on on helping the patients in your community get the care or access that they need.
00:52:28.960 --> 00:52:33.199
Um yeah, that's that that's very very cool.
00:52:33.599 --> 00:52:36.960
Well, thank you again, Michelle, for taking the time to do this.
00:52:37.039 --> 00:52:46.639
I feel like this is again, it's so nice to understand that I feel like a lot of the administrative sort of, I'm just administrative is a big umbrella, roles in research.
00:52:46.719 --> 00:52:56.639
If you're not specifically the PI or the coordinator running the trial or whatever, a lot of roles like yours, I feel like are kind of elusive and like what do they what do they do?
00:52:56.719 --> 00:53:00.400
And like what does it take to, you know what I mean, to manage a program like that.
00:53:00.559 --> 00:53:05.119
So thank you for kind of walking through and explaining how how a lot of this stuff works.
00:53:05.440 --> 00:53:06.000
Absolutely.
00:53:06.159 --> 00:53:07.440
Well, happy to talk.
00:53:07.679 --> 00:53:11.360
I feel like I uh touched on a a portion of it.
00:53:11.519 --> 00:53:14.400
Um day, I'm sure.
00:53:15.199 --> 00:53:16.159
On what you're doing.
00:53:16.800 --> 00:53:21.920
But certainly, uh yes, definitely uh it
takes a big team to do all this.
00:53:22.079 --> 00:53:27.119
So uh I think I'm pretty fortunate here to work with such amazing colleagues.
00:53:27.199 --> 00:53:33.760
So but yeah, a lot of a lot of smart and dedicated people are are doing this work.
00:53:33.840 --> 00:53:35.920
So excited to talk with you about it.
00:53:36.239 --> 00:53:37.039
That's awesome.
00:53:37.199 --> 00:53:38.880
Well, uh keep it up, right?
00:53:38.960 --> 00:53:41.280
For for everybody's sake, and and we appreciate it.
00:53:41.360 --> 00:53:44.000
But uh thanks and and I'm sure we'll talk soon.
00:53:44.400 --> 00:53:45.679
Thanks, Justin.
00:53:47.440 --> 00:53:49.920
I hope you enjoyed that conversation with Michelle.
00:53:50.079 --> 00:53:56.159
It's encouraging to hear from leaders who are so thoughtful about their role and are always working to improve the systems they're in.
00:53:56.400 --> 00:54:01.599
And speaking of encouraging, my next guest on the research participant side is Brian Blackman.
00:54:01.840 --> 00:54:08.079
Brian has an impressive career in clinical research himself, but today we talked about a different side of his experience.
00:54:08.320 --> 00:54:13.039
Brian is the caretaker for his dad who enrolled in a clinical trial last year.
00:54:13.199 --> 00:54:23.360
I've talked to several research participants, but we don't always get to hear from the caretakers, who, as you'll hear, play such a necessary and vital role in the research participant experience.
00:54:23.599 --> 00:54:37.840
Brian not only shares his personal story, but he also shares a little about how his experience as a caretaker, combined with his industry experience, led him to actually create something that solves a real problem in our industry for participants and caretakers.
00:54:38.079 --> 00:54:39.280
It's a wonderful discussion.
00:54:39.440 --> 00:54:43.199
So without further ado, I hope you enjoy my conversation with Brian.
00:54:44.719 --> 00:54:47.920
I am super excited to have Brian Blackman here with me.
00:54:48.079 --> 00:54:50.239
Brian, thanks so much for being on the podcast.
00:54:50.480 --> 00:54:51.679
Yeah, thanks a lot, Justin.
00:54:51.840 --> 00:54:52.559
Thanks for the invite.
00:54:52.800 --> 00:54:54.000
So I want to talk you.
00:54:54.239 --> 00:55:02.719
You have a very fascinating and interesting story that you're going to share, I know, about sort of being the on the caretaker side of taking care of somebody that's been in a trial.
00:55:02.960 --> 00:55:09.599
Before we get into the story, do you mind telling us uh a little bit about yourself and sort of how you came to where you're at now?
00:55:10.239 --> 00:55:10.960
Sure, yeah.
00:55:11.119 --> 00:55:16.480
So I'm one of these people that kind of got thrown into the world of clinical research by accident.
00:55:16.719 --> 00:55:18.400
I think a lot of people have this story actually.
00:55:18.719 --> 00:55:22.960
So I was never like I went to college and said that's what I want to do.
00:55:23.199 --> 00:55:31.599
But through a series of kind of like trial and error, like doing other jobs after graduating, I found this world and I actually really enjoyed it.
00:55:31.679 --> 00:55:39.360
So I throughout like, you know, the last 17 years or more, I've done just about everything you can do in like the clinical trial world.
00:55:39.519 --> 00:55:47.840
Um done study, startup, monitoring, closeouts, statistical reporting, kind of all of it.
00:55:48.079 --> 00:55:59.840
Was like doing some really cool stuff in like the decentralized clinical trial world before it was even a thing, like you know, traveling to people's homes and actually collecting biospecimens and things like that.
00:55:59.920 --> 00:56:02.079
It was just really, really fun stuff.
00:56:02.239 --> 00:56:02.480
Yeah.
00:56:02.639 --> 00:56:10.559
But like with most people, I kind of at some point you get a little burned out and you're like, this is this is a lot, and there's a lot of it it's a tough job.
00:56:10.719 --> 00:56:18.960
Uh so I did take a little break and I went and worked on the payer side of the industry for a little bit, which was incredibly interesting.
00:56:19.199 --> 00:56:23.039
And I kind of feel like I need to say this because I I tell a lot of people this.
00:56:23.199 --> 00:56:27.119
I think that more people who are doing clinical trials should have that experience.
00:56:27.199 --> 00:56:36.480
Because from my perspective of like doing this work, yeah, I always kind of thought that the the the whole world is just from drug discovery up to FDA approval.
00:56:36.559 --> 00:56:37.840
And then it's like everything stops.
00:56:37.920 --> 00:56:42.880
And what I realized really quickly was these big pharma companies, especially that's not true at all.
00:56:43.039 --> 00:56:51.039
Like that's when a lot of times they think the work actually begins because they've got to get it to market, they've got to get it to people, they've got to get it on formulary and get people to use it.
00:56:51.119 --> 00:56:54.079
And yeah, it was a very interesting experience.
00:56:54.239 --> 00:57:03.920
But after doing that for a little bit, I had the opportunity to come back to where I work now, which is the Duke Clinical Research Institute, to help with their innovation center called iCubed.
00:57:04.159 --> 00:57:16.800
And so it was a nice change because I'm most definitely still in kind of you know the day-to-day of what the clinical research world needs and areas to make improvements, but it's no longer the kind of grind that it used to be.
00:57:16.960 --> 00:57:19.840
So that brings me up to what I've done and where I am now.
00:57:20.079 --> 00:57:20.880
Yeah, that's awesome.
00:57:20.960 --> 00:57:22.159
No, that's a great background.
00:57:22.239 --> 00:57:40.320
Well, and I think that'll and and you'll I know you'll touch on this in the in your story, but I think that uh your background sort of helps to shape what your experience and and and
give a lot of not credibility, but a lot of insight, I think, into what's happened and stuff with your story as a caregiver.
00:57:40.559 --> 00:57:41.760
So I guess let's jump into it.
00:57:41.920 --> 00:57:50.000
If you don't mind, sort of let's start at the beginning, kind of tell us how this came about and and what what we're talking about here with the clinical trial.
00:57:50.320 --> 00:57:56.400
Yeah, so um you're right, because it does kind of shape, I think, leading into this maybe differently than other people.
00:57:56.480 --> 00:58:01.920
Because after doing this for so long, you kind of think like, oh, I'm ready for whatever people are gonna throw at me.
00:58:02.079 --> 00:58:12.079
And so it all it all became very different when my dad, well, so let's step back, like you said, about eight years ago, he was diagnosed with cancer, multiple myeloma, which is a blood cancer.
00:58:12.400 --> 00:58:20.000
And it was kind of a a long and difficult diagnosis because the weight usually presents itself is through back pain and things like that.
00:58:20.079 --> 00:58:22.320
And he's had back problems basically his entire life.
00:58:22.400 --> 00:58:24.639
So it was disguised in a lot of other things.
00:58:24.960 --> 00:58:27.199
He eventually he got diagnosed with it.
00:58:28.320 --> 00:58:35.920
He got put on in a the standard of care for chemo, he had a stem cell transplant and actually responded quite well to those.
00:58:36.559 --> 00:58:44.559
And the for his specific case, it was never like something where you know he sat down with a doctor that was like, You've got 18 months to live or anything like that.
00:58:44.639 --> 00:58:53.519
They were like, We think that this is very manageable, we think that we can, you know, we can't cure it, but we can definitely try to treat this for as long as possible.
00:58:53.679 --> 00:58:54.000
Yeah.
00:58:54.320 --> 00:59:02.159
So the caregiver side of this was really interesting because this is even before he was ever enrolled in a clinical trial.
00:59:02.239 --> 00:59:08.960
This is just like, well, now somebody has a cancer that requires weekly chemo infusions.
00:59:09.119 --> 00:59:17.519
And so, you know, how it and the because it was uh a cancer that resulted in a lot of physical pain, he couldn't drive himself.
00:59:17.679 --> 00:59:23.599
And so my mom ended up being very involved in this, like, you know, driving him to all of his appointments while she's still working.
00:59:23.760 --> 00:59:25.360
So that was very difficult.
00:59:25.519 --> 00:59:41.119
And they managed it for a while, and thankfully, throughout that, since that happened eight years ago, since then my mom is retired and in her wonderful retirement now, like this is what she's doing is taking care of my dad and driving him to and from doctors' visits.
00:59:41.360 --> 00:59:44.159
Yeah, oh my goodness, that is a lot.
00:59:44.639 --> 00:59:45.840
It's it's a lot, like you said.
00:59:45.920 --> 00:59:55.760
I mean, for somebody that anybody that kind of has any kind of diagnosis like that, like your the the the caregiver aspect is such an important part of that, right?
00:59:55.840 --> 00:59:59.280
Like you just can't nobody can manage that on their own, right?
00:59:59.440 --> 00:59:59.760
Right.
00:59:59.920 --> 01:00:00.800
That's yeah.
01:00:01.519 --> 01:00:11.119
And so my dad enrolled in a clinical trial about a year ago, but before that, he had another opportunity to roll in a clinical trial, and everybody actually was really excited about it.
01:00:11.199 --> 01:00:16.480
But then we found out that he was not eligible due to the fact that he had already had a stem cell transplant.
01:00:16.719 --> 01:00:23.360
So, like there was this opportunity where we were like, hey, here's something that you might qualify for, and then we realized, oh, actually you're not.
01:00:23.440 --> 01:00:27.119
So it's kind of like that roller coaster of emotion, which I hear a lot of people talk about.
01:00:27.280 --> 01:00:39.760
But then about a year ago, there was another opportunity for a trial, and this was actually a um it's it's kind of like a drug added to standard of care therapy kind of thing.
01:00:39.920 --> 01:00:42.719
So it makes the scheduling quite difficult.
01:00:42.800 --> 01:00:43.519
I'll say that.
01:00:43.679 --> 01:00:52.320
But the interesting piece was my parents know that I work in the clinical trial industry, but they don't really know what I do, and it's like kind of hard to explain it to them.
01:00:52.480 --> 01:00:57.920
And sometimes when I tell them like really what I do, they just kind of shake their head and they're like, I still don't get it.
01:00:58.079 --> 01:00:59.440
But um, yes, yes.
01:00:59.519 --> 01:01:04.559
I think everybody that works in the research industry right now listening is like, yeah, I've had that conversation with my parents.
01:01:04.719 --> 01:01:04.960
Yep.
01:01:05.199 --> 01:01:14.880
Yeah, my dad's like, you're not a doctor, you're not a nurse, but so anyway, so he calls me up and he's like, Hey, so I have another clinical trial, potentially.
01:01:15.199 --> 01:01:21.199
I just left talking to the nurse, and I've got like I want to talk to you about it.
01:01:21.280 --> 01:01:24.639
And I was like, Absolutely, like this is my time to shine, kind of thing, right?
01:01:24.800 --> 01:01:26.800
Like, I can come in and show you this.
01:01:26.960 --> 01:01:33.440
And my mom, who has historically been kind of the one to help with this care, she was like, I don't know what any of this stuff means.
01:01:33.599 --> 01:01:35.519
And I was like, Don't worry, I'll help you out.
01:01:35.679 --> 01:01:36.239
I got this.
01:01:36.559 --> 01:01:45.840
So eventually, one of the first problems that I realized with trying to share information about a trial with caregivers is that I was like, just email me over the forms.
01:01:46.000 --> 01:01:53.760
Because in my line of work, if I I email consent forms to
colleagues or to whatever, to sites, and I'm like, here you go, and all this kind of stuff.
01:01:53.840 --> 01:01:55.760
And he was like, Well, it's sitting on my kitchen counter.
01:01:55.840 --> 01:01:56.800
How am I supposed to give it to you?
01:01:56.880 --> 01:01:58.320
And I was like, Oh, of course, right.
01:01:58.559 --> 01:02:01.519
So there was a time sensitivity to this.
01:02:01.679 --> 01:02:03.039
He needed to make a decision soon.
01:02:03.119 --> 01:02:09.519
So I was able to go over there and I sat down and I looked at the consent form, which at that point was pretty much all he was given.
01:02:09.679 --> 01:02:14.480
And it was dense, it was so dense, it was like 55 pages long.
01:02:14.880 --> 01:02:22.480
And the nested within that was a schedule of events that had all because it was tied to standard of care, it was just like incredibly confusing.
01:02:22.800 --> 01:02:27.679
And my parents were just like, we really don't know what to do.
01:02:27.760 --> 01:02:29.840
And they were basically looking to me for guidance, right?
01:02:30.320 --> 01:02:31.280
What should we do?
01:02:31.840 --> 01:02:38.239
The the the the PI, who was also his oncologist, okay, was incredibly helpful, right?
01:02:38.400 --> 01:02:41.599
He was like, I'm happy to answer any other questions you have.
01:02:42.079 --> 01:02:47.360
His nurse, who was also acting as the coordinator for the trial, that's not her full-time job.
01:02:47.519 --> 01:02:52.159
She is also a nurse for his regular oncology care as well.
01:02:52.639 --> 01:02:59.760
So one of the first things I did was I was like, let me just call her and see if I can get some basic stuff answered.
01:03:00.000 --> 01:03:00.400
Yeah.
01:03:00.639 --> 01:03:07.760
And she was like, I have to be honest with you, this is I I don't, I'm probably not the best person to ask this to.
01:03:07.920 --> 01:03:09.519
This is a fairly new trial.
01:03:09.599 --> 01:03:13.360
I've got a cheat sheet here that I'm looking at, and I don't really know the answers.
01:03:13.599 --> 01:03:17.920
You could try calling the PI, but he's not going to be able to take your call for a while.
01:03:18.079 --> 01:03:21.840
She was like, Why don't you try calling the nurse navigator at the oncology center?
01:03:21.920 --> 01:03:32.239
And so I was like, Okay, so I called the nurse navigator, and she was so incredibly nice, but she was also on the verge of tears because she was like, I'm one of two nurse navigators for the whole cancer center.
01:03:32.480 --> 01:03:33.760
And I really don't know.
01:03:33.920 --> 01:03:35.760
She was like, Do you need an Uber ride or something?
01:03:35.840 --> 01:03:38.320
And I was like, No, no Uber ride.
01:03:38.559 --> 01:03:49.760
But yeah, it just, you know, it was incredibly, I guess what I'm trying to say was incredibly eye-opening for me, because in my mind, I'm I've been the on the other side of this.
01:03:49.840 --> 01:03:56.719
I've been people creating consent forms
and creating study documents, and said, sure, anybody would understand this.
01:03:56.880 --> 01:03:57.199
Yeah.
01:03:57.440 --> 01:04:14.239
And the other piece of this that I really had never considered and always taken for granted is that from my dad and my mom's perspective here, and now my perspective, there seemed to be this urgency to everything.
01:04:14.559 --> 01:04:25.519
And there wasn't this luxury of being able just to sit around and say, Well, let's think about it, and I don't know, come back to it in a week or two weeks, or it'll try to answer as many questions as we can.
01:04:25.599 --> 01:04:29.360
Because they were like, He can come in, he needs to come in tomorrow, basically, to start.
01:04:29.760 --> 01:04:30.079
Yes.
01:04:30.320 --> 01:04:30.639
Wow.
01:04:30.800 --> 01:04:32.559
Anyways, long story short, he enrolled.
01:04:32.800 --> 01:04:33.519
Yeah, okay.
01:04:34.159 --> 01:04:38.320
He's uh so you just took, I mean, at that point, you didn't get really any answers.
01:04:38.719 --> 01:04:39.360
No, I didn't.
01:04:39.760 --> 01:04:46.800
I didn't get and and it was the questions that I had were more about kind of the logistics of things.
01:04:47.039 --> 01:04:54.559
The consent form did a great job of saying, here are the risks, here's kind of what the what this study is trying to accomplish.
01:04:54.719 --> 01:05:01.440
But I was trying to figure out how many more times is he gonna have to go into his to to see his doctor.
01:05:01.679 --> 01:05:04.159
Are these gonna be concurrent with his regular visits?
01:05:04.239 --> 01:05:05.840
Are they gonna happen at different times?
01:05:06.000 --> 01:05:12.400
And yeah, we found out later, because this wasn't in any of the documents that he received, is that they weren't actually concurrent.
01:05:12.480 --> 01:05:17.440
It's this totally new visit and all this kind of stuff, but but that wasn't clear just looking at the documents, yeah.
01:05:18.000 --> 01:05:22.960
Was it wasn't clear, and the his nurse is amazing, like really, really great.
01:05:23.039 --> 01:05:26.320
But she was also like, I I am not quite sure either.
01:05:26.480 --> 01:05:45.760
So yeah, well, that's crazy too, because to your point, you know, uh because of the urgency and because like they wanted to start tomorrow, the logistics that you're talking about, I I'm just it's like asking somebody to to can you commit today to date somebody for the next six months, but I don't know what the commitment level is.
01:05:45.840 --> 01:05:47.840
Like how many, how many times am I supposed to take them out?
01:05:47.920 --> 01:05:48.960
How many you know what I mean?
01:05:49.039 --> 01:05:55.599
Like all of the legit what is the commitment level that I have to say yeah, that I'm saying yes to right now.
01:05:55.679 --> 01:05:59.599
And if I don't have those answers, I still have to say yeah, that's a that's a tough spot to be in.
01:06:00.159 --> 01:06:00.719
That's right.
01:06:00.880 --> 01:06:10.079
And there's the other piece in all of this is my my dad in particular really, really trusts his his doctor, his oncologist.
01:06:10.480 --> 01:06:17.039
And so, in fact, so much so that he's one of these people that like the oncologist moved from one hospital to another.
01:06:17.199 --> 01:06:22.159
My dad followed him, like went said, I'm gonna pick up all my care and I'm gonna go to this new new new place.
01:06:22.639 --> 01:06:32.239
So I I think what my dad wanted, which the doctor wasn't gonna say, my dad basically wanted him to say, do this or don't do this.
01:06:32.400 --> 01:06:43.199
Just give him, like, you know, don't don't turn it over to me to say like this is now your decision, because my dad didn't know what the like, you know, to your point, like didn't have all the information, didn't know what was gonna be best for him.
01:06:43.519 --> 01:06:53.119
Well, you know what, that brings up a good point, Brian, because you and again, you being in this industry, you know, we talk all the time, as you know, about increasing enrollment.
01:06:53.280 --> 01:06:57.360
Like, one of the ways that we talk about increasing enrollment is to get the physician more involved, right?
01:06:57.440 --> 01:07:08.079
If they're a PI, like the if they go to enroll somebody or they explain a study or give a study opportunity to one of their own patients as their clinician, people are much more likely to say yes, for this reason.
01:07:08.159 --> 01:07:12.400
To your point, your dad uh really trusts his physician, his oncologist.
01:07:12.559 --> 01:07:21.199
Well, at the same time, if you're used to your oncologist giving you clinical advice, and in the clinical side, they're saying, I think you should do this.
01:07:21.440 --> 01:07:27.039
In the research side, now they have to take off that hat and say, I can't tell you I think you should do this, I'm just giving you the opportunity.
01:07:27.119 --> 01:07:36.559
That is it's sort of a an awkward kind of like, Well, I'm looking for this person to just give me the same kind of clinical advice that they've given me in the past, and now they're not.
01:07:36.639 --> 01:07:38.480
There, it's more vague and like what is going on.
01:07:38.639 --> 01:07:40.320
So, yeah, that's pretty tough.
01:07:40.639 --> 01:07:46.880
Yeah, and I think that that kind of relationship just to what you're pointing out has like already been established, right?
01:07:46.960 --> 01:08:06.000
Like, there's um it nobody wants to call it like a power dynamic because that's not maybe a fair way to categorize it, but there is this understanding from my parents, and I think it's shared from a lot of people, not just in clinical trials, but uh people who are patients, to say, you are the one who knows more about this than I do.
01:08:06.320 --> 01:08:08.960
And I'm looking to you for for guidance here.
01:08:09.280 --> 01:08:10.000
Right, right.
01:08:10.159 --> 01:08:14.480
And and when they didn't get that from their
oncologist, they came to you, right?
01:08:14.719 --> 01:08:15.519
They came to me.
01:08:15.679 --> 01:08:16.000
Yes.
01:08:16.239 --> 01:08:24.640
And uh I I think I I probably more than anybody am like the biggest advocate for the good of clinical trials.
01:08:24.800 --> 01:08:27.359
Like I think that we could clinical trials are great.
01:08:27.520 --> 01:08:31.600
We don't I actually don't think we hear enough about the positives of clinical trials.
01:08:31.760 --> 01:08:36.079
I would love to get a panel basically of just like success stories of clinical trials.
01:08:36.319 --> 01:08:41.520
But even me in that perspective, it was hard for me to just blindly say yes, do it, you know?
01:08:41.760 --> 01:08:42.079
Right?
01:08:42.239 --> 01:08:45.680
Yeah, well, I mean, when you don't have all the information, like you said, that's tough.
01:08:46.880 --> 01:08:47.279
Yeah.
01:08:47.520 --> 01:09:00.319
So the but but I guess one of the other things that and this is probably the biggest piece, is that we've spent I don't know how much time now just talking about the decision making about like whether or not you actually get into the trial.
01:09:00.399 --> 01:09:04.239
And I realized that's kind of when the job begins, right?
01:09:04.399 --> 01:09:12.479
So then you know, my dad's job and my job as like you know, helping him navigate this, his actually the visits that he has are local to me.
01:09:12.560 --> 01:09:14.399
So he drive he travels for them.
01:09:14.640 --> 01:09:15.920
Um that's when it all starts.
01:09:16.159 --> 01:09:20.800
So I show up with him, I sit down with him usually beforehand.
01:09:20.880 --> 01:09:26.640
He has to do kind of this like an e-diary, basically, to like you know, track how he's feeling, any symptoms and stuff like that.
01:09:26.800 --> 01:09:31.439
Yeah, if he were left to his own, he would not do any of these things.
01:09:31.600 --> 01:09:34.079
And I don't think that that is unique to him.
01:09:34.239 --> 01:09:46.960
He's of a certain age and just overall like use of technology that I think he he would probably before doing any of that, he would write it down in a notebook and hand it over to his nurse in in person.
01:09:47.359 --> 01:10:04.159
But I think this is very important because in all of the engagement that takes place in his trial, meaning like the reminders to like do your e-diary, like here's when your appointment is, and all of that, there still is this that there's not a clear integration point for caregivers.
01:10:04.720 --> 01:10:10.640
The the messaging is sent to him, the reminders are sent to him, yeah, and that's kind of where it falls off.
01:10:10.800 --> 01:10:14.800
And I'm trying to actively push myself into the conversation.
01:10:15.199 --> 01:10:19.199
And when people realize that, they'll they'll loop me in more.
01:10:19.520 --> 01:10:24.479
But his phone number's in the database, his email address is in the database, and it's not mine.
01:10:24.720 --> 01:10:31.600
And so I've realized now that there's this system that's not set up very well for pulling in caregivers.
01:10:32.560 --> 01:10:33.359
That's a good point.
01:10:33.520 --> 01:10:34.319
That's a really good point.
01:10:34.399 --> 01:10:45.119
Yeah, I think the assumption, again, on the research side is that if you know you you inform them through the the consent process, not just the document, but the process, obviously, tell them what's going on.
01:10:45.359 --> 01:10:51.439
If they say yes, they want to be in the study, then, you know, they understand they're gonna do all this stuff.
01:10:51.520 --> 01:11:10.000
And and the the compliance piece of it, I think, is is an assumption that the research side makes is that, yeah, of course, people will fill out their e-diaries and you know, because again, we've built in these processes and it's all process stuff, which is reminders and text messages and my chart notes, and you know, whatever it is.
01:11:10.079 --> 01:11:19.039
Like, here's just a a reminder of your visit coming up, and so then we just assume of course they're gonna do it, and yeah, that doesn't happen very often.
01:11:19.279 --> 01:11:27.439
Yeah, and I do think that there is a a group out there that will do that, right?
01:11:27.520 --> 01:11:42.720
Like, this is not to say that those things aren't useful across the board, but I mean I can tell you now, from my experience doing this with my dad, and interestingly, because people of his age and whatever, they they they just talk.
01:11:42.800 --> 01:11:48.880
And so now when I show up with him at a like he knows everybody there, and he knows everybody else basically who's in the trial.
01:11:49.119 --> 01:12:00.000
And so they talk about this, and uh that I I've confirmed that it's not just an isolated thing, he knows all these people, and they all talk about how you know they're all there with their caregivers.
01:12:00.399 --> 01:12:10.880
Sometimes it's is sometimes it's a kid, sometimes it's their wife, a lot of times it's like a neighbor or somebody who just drives them because a lot of these people like can't really drive themselves very easily.
01:12:11.039 --> 01:12:11.359
Sure.
01:12:11.520 --> 01:12:27.279
My dad still can't drive himself, and so again, when we think about let's get people to stick through the trial, let's get people to be engaged, to show up on time, to remember what they're supposed to do and actually do it.
01:12:27.520 --> 01:12:36.640
Yeah, I think we've not done a good job of arming everybody around that person with the same information because it's really hard to do all of this alone.
01:12:36.720 --> 01:12:48.640
And so, you know, I've I've I've thought now long and hard about how can I get as much information about the trial as my dad because I want him to be a successful participant.
01:12:48.880 --> 01:12:54.079
I don't want him to not do something correctly and cause a protocol deviation or drop out or something like that.
01:12:54.399 --> 01:12:54.800
Right.
01:12:55.039 --> 01:12:55.359
Right.
01:12:55.600 --> 01:13:01.119
But but it's just amazing how much work it takes from others to keep that from to keep that to uh to happen.
01:13:01.199 --> 01:13:02.159
So absolutely.
01:13:02.399 --> 01:13:11.520
Well, and I think uh built into your story, obviously, you you were obviously you said close enough to your parents that you drove over there to review the documents.
01:13:11.680 --> 01:13:14.960
I mean, most people don't have that, you know what I mean?
01:13:15.039 --> 01:13:19.600
Like what if they don't have the ability to drive right over that day or the next day to review?
01:13:19.680 --> 01:13:22.960
How do you get how do you get the information, right?
01:13:23.279 --> 01:13:23.840
That's right.
01:13:24.000 --> 01:13:31.840
And it's I think then what happens is, and I'm learning more about this, people are looking for information.
01:13:32.000 --> 01:13:46.720
If they can't get it from their doctor, they can't get it from their coordinator, or they don't have somebody to drive over, like you said, they're gonna look to their neighbors or their friends or people who they may know who may not have 20 years of clinical research experience like I do.
01:13:46.960 --> 01:13:47.199
Right.
01:13:47.439 --> 01:13:54.640
And I mean, good, good on them for actually trying to get answers, but it's also they should they shouldn't have to work that hard, I think.
01:13:54.880 --> 01:13:55.199
Right.
01:13:55.359 --> 01:13:56.079
No, I agree.
01:13:56.159 --> 01:13:56.560
I agree.
01:13:56.640 --> 01:13:58.640
I mean, but yeah, it should not be this hard.
01:13:58.880 --> 01:14:00.720
We have the technology, you know what I mean?
01:14:01.359 --> 01:14:01.760
Yeah.
01:14:02.000 --> 01:14:19.600
So the other uh interesting thing in all of this is that I did a side experiment in this where I took my dad's trial documents and I uploaded them, basically created a version of this because uh an e-e-binder basically of his documents.
01:14:19.680 --> 01:14:30.800
And one of the reasons I did this is because his primary care doctor was also really interested in his trial, which was basically because my dad has other comorbidities and he was just like, Oh, you're in a clinical trial.
01:14:30.880 --> 01:14:32.000
Well, tell me what it's like.
01:14:32.159 --> 01:14:35.680
And you know, he you know, did really know all the details or whatever.
01:14:35.840 --> 01:14:46.000
And so I did this, and it was basically like a way, because again, when you think of caregivers, caregivers span a pretty wide swath of people.
01:14:46.239 --> 01:15:02.880
Primary care doctors are most definitely a very key stakeholder as a caregiver, and it was a success in that my dad was able to share this information with the primary care doctor who logged in, looked at everything, all of his documents that he had, and said, This is really interesting.
01:15:03.199 --> 01:15:12.000
And he my dad didn't
have to fax over documents or wait until his next visit three months from now to hand over a folder of papers and all that kind of stuff.
01:15:12.159 --> 01:15:14.239
So it was it was pretty cool.
01:15:14.399 --> 01:15:35.039
And I think that it's just another example of how we've built, I think, technologies for lots of other stakeholders in in running a trial to do this stuff, but we haven't really yet put a lot of resources or effort into making all of this information and decision-making ability in front of participants and caregivers.
01:15:35.680 --> 01:15:37.760
Uh that's a that's a fantastic point.
01:15:37.840 --> 01:15:54.560
I I mean, I'm just thinking in terms of you're talking about like solutions or or you know things that have been developed in the research industry to your point that have been created just to make things either more efficient or make it whatever.
01:15:54.800 --> 01:16:04.800
If it's efficient or just to improve the process or whatever, there are a million of those products out that help the pharma companies, that help the research sites, right?
01:16:04.880 --> 01:16:10.880
Like the coordinators, they all I mean, all of them have you know the CTMSs and systems and e-reg binders themselves, right?
01:16:10.960 --> 01:16:13.600
That that manages all the research stuff.
01:16:13.840 --> 01:16:21.359
I can't think of anything that is literally just geared towards patients that uh helps them, right?
01:16:21.520 --> 01:16:22.479
Like, you know what I mean?
01:16:22.560 --> 01:16:26.880
Like what you're describing is like a a binder essentially that they can own.
01:16:27.039 --> 01:16:30.319
Like as a research participant, your dad owns that stuff.
01:16:30.399 --> 01:16:35.279
Like, this is his study, it's his documents, he can share it with his physician, share it with you.
01:16:35.359 --> 01:16:38.960
Like, that is that's a great concept.
01:16:39.279 --> 01:16:42.960
Yeah, it it changes the role of a participant at that point, right?
01:16:43.119 --> 01:16:48.079
Like they are more, they have more ownership in this, they have more vested interest in this.
01:16:48.319 --> 01:17:00.000
It's just like now I was actually talking to somebody the other day about how when you buy a house now, or you we're we're not at the point anymore where we hand over like big giant stacks of papers to people after they buy a house.
01:17:00.079 --> 01:17:01.920
You get documents emailed to you and everything.
01:17:02.000 --> 01:17:19.439
And so it does seem like we're at a point, like a tipping point where participants, caregivers, and other people have been really kind of left behind for quite a while as it relates to this being pulled into the process, being pulled into the decision making and everything.
01:17:19.600 --> 01:17:25.199
And I'm not talking about early on, like, you know, let's develop protocols that have patient input and stuff like that.
01:17:25.359 --> 01:17:27.039
I think we've done a lot of really good work
with that.
01:17:27.279 --> 01:17:33.039
It's sort of like, okay, after somebody's enrolled, they deserve more than just a folder full of papers.
01:17:33.279 --> 01:17:33.520
Yes.
01:17:33.680 --> 01:17:37.199
No, I'm with you because I'm thinking on the clinical, this is the problem, right?
01:17:37.279 --> 01:17:48.319
Like research, to your point, you've had this experience in your past, you said when you went to the payer side of of understanding how research fits within the larger context of healthcare in general, right?
01:17:48.479 --> 01:17:49.920
And and that world.
01:17:50.159 --> 01:17:56.560
In the same way, I feel like clinical care, they've they've already addressed this problem with my chart, right?
01:17:56.640 --> 01:17:57.920
Or whatever their system is for that.
01:17:58.640 --> 01:18:17.359
And so now, and and you know this too, but just for for patients on the patient side, I know a lot of systems have tried to utilize my chart for research purposes, but again, all of those bells and whistles benefit the research teams, it benefits the physicians, it benefits the the PIs, whatever, the coordinators.
01:18:17.520 --> 01:18:20.159
It doesn't help the patient themselves.
01:18:20.319 --> 01:18:28.640
It doesn't actually, you can't go into my chart if you're in a research trial and understand what your study is and your visits and all that stuff.
01:18:28.800 --> 01:18:54.000
So you're talking about something completely separate, sort of like a My Trail, I guess, but for the research side, I yeah, I just never and the other thing that I'll tell you after living this with my dad and being the one who drives him to his his appointments, and the biggest questions that I had were not really things that could be found in the protocol.
01:18:54.079 --> 01:18:55.760
It was stuff like where do I park?
01:18:55.920 --> 01:18:59.520
How do I get my my parking pass reimbursed?
01:18:59.760 --> 01:19:08.720
All of these kinds of things that again, people get that, but they get it in a piece of paper that gets crumbled up and potentially lost and forgotten.
01:19:08.800 --> 01:19:17.680
And so I think that there's again, I as a participant, as a caregiver, I think that there's a lot of really valuable information.
01:19:17.920 --> 01:19:21.359
Sometimes it's stuff that's not even in a protocol, it's not in a consent form.
01:19:21.439 --> 01:19:27.199
It's really these logistics things that help keep people, it gives people, I think, overall a better experience.
01:19:27.520 --> 01:19:28.800
I I think that's a great point.
01:19:28.960 --> 01:19:37.119
And the the wayfinding, like where to park, that question would obviously not gonna be a proto-power consent, but that's something a caregiver typically would need to know, right?
01:19:37.199 --> 01:19:41.359
Like in a lot of cases, like as in yours, you would be driving your dad to these appointments.
01:19:41.520 --> 01:19:47.520
He's not necessarily thinking, I don't, I don't know, like he's just in the car and you're driving, so you know where you're going.
01:19:47.760 --> 01:19:48.720
You know, take me to my appointment.
01:19:48.880 --> 01:19:55.840
It's like, but I if nobody's told you where to go, especially if you get down to some of these hospitals, man, they're it's like a maze.
01:19:55.920 --> 01:19:57.439
Yeah, it's on purpose.
01:19:58.159 --> 01:19:58.720
That's right.
01:19:58.800 --> 01:20:02.000
Because then once you once you find the building, the job started, you know.
01:20:02.159 --> 01:20:07.600
Then it's like, okay, which hallway, which elevator, and they're all like, I'm there literally with a map that's printed out.
01:20:07.760 --> 01:20:13.279
It's like, look for the purple arrows, and then go down a floor, and then you'll see a green, like smiley face on the wall.
01:20:13.760 --> 01:20:17.039
Yep, it is it's a literally that's right, yes.
01:20:17.279 --> 01:20:24.399
But but I mean, I think to your point about uh a system and and so you said that you've you've sort of created the system on your own.
01:20:24.479 --> 01:20:31.279
It was it's you said it started out as sort of a it started out as just kind of a uh like would this even work?
01:20:31.359 --> 01:20:42.000
Yeah, and it did work, and so I I did as much as I could with my limited technical skills, and then was really fortunate in that a good friend of mine is a real true builder of these things.
01:20:42.079 --> 01:20:57.199
And so I've worked with him and he's built to together we've put together a what I think is a tremendous resource for participants and for caregivers, and it essentially takes all of these documents that people receive, it puts them in a digital place that you can have access to, you can share it.
01:20:57.279 --> 01:21:04.159
So, like my dad can or my mom or whoever wants to log in and say, I want Brian to have access to this.
01:21:04.319 --> 01:21:08.800
Yeah, I can log in and I can see all of his uh everything that he's doing.
01:21:09.039 --> 01:21:15.199
I can follow up with my dad to say, Hey, by the way, did you know that X, Y, or Z was going to be happening?
01:21:15.439 --> 01:21:17.520
And just make sure that he's prepared.
01:21:17.760 --> 01:21:26.479
But it but but another thing that we did that I'll say really quickly, because I think it's one thing just to give people documents that that solves part of the problem.
01:21:26.640 --> 01:21:32.399
The other really interesting thing is that when you have those, like this was the problem that I had, my dad has, my mom has.
01:21:33.199 --> 01:21:37.279
Looking at that big stack of papers, you really have three bad options if you have a question.
01:21:37.439 --> 01:21:40.159
One is you can hopefully find the answer in those.
01:21:40.319 --> 01:21:43.119
He didn't know which document to look for to get the answer.
01:21:43.279 --> 01:21:45.600
And then if he did, did you actually understand it?
01:21:45.920 --> 01:21:49.359
The second thing is you could call
your coordinator and ask them.
01:21:49.520 --> 01:21:50.960
And I will tell you this now.
01:21:51.199 --> 01:22:03.760
Every single time I go to a visit with my dad, yeah, the nurse who is treating it, her phone is just like buzzing nonstop with, you know, somebody's got a question or somebody's late, or can you reschedule this or you know, whatever?
01:22:04.159 --> 01:22:10.560
So we don't want to continue to push questions to coordinators, trying to figure out is there a deflection or a support way to do this.
01:22:10.800 --> 01:22:17.920
The third thing that people do, like I said earlier, is they're going to social media, they're going to ChatGPT or Reddit.
01:22:18.159 --> 01:22:23.119
Interestingly, I found a Facebook group that was very specific just for my dad's clinical trial.
01:22:24.399 --> 01:22:27.039
Seriously, is it like just for his trial?
01:22:27.199 --> 01:22:29.279
Yeah, you had to like request to join.
01:22:29.439 --> 01:22:31.119
Of course, I requested, I got in.
01:22:31.199 --> 01:22:34.479
Nobody asked me for any kind of like verification that I was in the trial.
01:22:34.720 --> 01:22:35.439
It's amazing.
01:22:35.680 --> 01:22:38.159
But it's people sharing information about the trial.
01:22:38.399 --> 01:22:43.039
And so again, they people are looking for uh for this information.
01:22:43.119 --> 01:22:47.760
But what I was gonna say is that just giving them the documents doesn't always solve the the problem.
01:22:47.920 --> 01:22:55.439
What we do is we now allow people just to ask questions about their study, and they don't have to know which document has the answer or how to interpret it.
01:22:55.520 --> 01:23:02.000
And what we do is we scan across all the documents that they've been given, we find the answer, and we put it back in front of them in plain language.
01:23:02.159 --> 01:23:07.439
So if you were given a Fitbit or something and you want to know, do I wear this Fitbit in the shower?
01:23:07.680 --> 01:23:08.800
Do I wear it when I exercise?
01:23:08.960 --> 01:23:10.319
When do I need to take it off?
01:23:10.560 --> 01:23:14.960
These are going to be things that are buried in instructions or manuals or SOPs somewhere else.
01:23:15.199 --> 01:23:15.520
Yeah.
01:23:16.079 --> 01:23:17.199
You can just ask that question.
01:23:17.359 --> 01:23:20.239
It searches across everything you've been given and it gives you the answer back.
01:23:20.479 --> 01:23:21.119
That's awesome.
01:23:21.199 --> 01:23:21.760
That is awesome.
01:23:21.920 --> 01:23:23.119
And what is the system called?
01:23:23.359 --> 01:23:24.399
It's called clear trials.
01:23:24.720 --> 01:23:25.359
Clear trials.
01:23:25.520 --> 01:23:26.159
Clear trials.
01:23:26.239 --> 01:23:26.479
I love it.
01:23:26.560 --> 01:23:30.720
I I think that's that's a fantastic concept and and idea.
01:23:31.039 --> 01:23:35.680
So then with your and to your point, the fact that there are, and this is what happens with anybody, right?
01:23:35.760 --> 01:23:41.439
If you don't, if there's not a solution out there, something like clear trials, right?
01:23:41.600 --> 01:23:43.439
Then people will make their own communities.
01:23:43.520 --> 01:23:49.520
Because again, uh, you know, clinical care is similar, but research is very much a community-involved activity.
01:23:50.000 --> 01:23:54.800
You don't just join a trial and independently go in there and do your thing and go home or whatever.
01:23:55.119 --> 01:24:01.840
You know, this you have caregivers, you have uh friends, family, whatever, support people, no matter what you're doing in a trial.
01:24:02.079 --> 01:24:08.720
So if that sense of community, like you're saying, like people found it on Facebook because that's an easy way to set it up.
01:24:09.039 --> 01:24:15.520
I I yeah, I think that that really does show that people are are interested in this level of help and support.
01:24:15.600 --> 01:24:17.039
And they that's right.
01:24:17.199 --> 01:24:18.159
They're searching for it.
01:24:18.319 --> 01:24:23.279
And even if it's somebody who's not searching on Facebook, it's somebody like my dad who's searching in the waiting room.
01:24:23.520 --> 01:24:27.680
He's talking to people, and he what it they they want that sense of community.
01:24:27.760 --> 01:24:32.800
They want to know that they're not doing this alone, that there are other people who are going through the same experiences as them.
01:24:33.039 --> 01:24:33.279
Right.
01:24:33.439 --> 01:24:34.319
Absolutely, absolutely.
01:24:34.560 --> 01:24:35.279
No, that's awesome.
01:24:35.359 --> 01:24:35.760
That's awesome.
01:24:35.920 --> 01:24:41.840
So then, as your dad has gone through, so he's using is your dad using clear trials you sent forward.
01:24:41.920 --> 01:24:42.640
Yeah, it is his study.
01:24:42.960 --> 01:24:44.079
Yeah, we set it up just for him.
01:24:44.159 --> 01:24:44.399
Yep.
01:24:44.640 --> 01:24:45.199
That's awesome.
01:24:45.279 --> 01:24:46.000
That's so cool.
01:24:46.159 --> 01:24:48.319
So is that like what is hit?
01:24:48.560 --> 01:24:53.279
I know you're speaking for him at this point, but like what has his experience been with that?
01:24:53.359 --> 01:24:56.640
Is he does he feel more confident or do I mean has he talked about it?
01:24:56.960 --> 01:25:04.000
Yeah, in fact, it's almost given him a sense of preparedness, I think might be the word that he didn't have before.
01:25:04.159 --> 01:25:17.600
Yeah, and also for my mom, I'll say, you know, the between the two of them now, I think what they what they're able to understand is if you remember, I think when we started this conversation, I think one of the things that was really confusing for them and for me was just the schedule.
01:25:17.760 --> 01:25:25.439
Like what happens next when, and now they have a much better sense of understanding exactly what's gonna take place.
01:25:25.680 --> 01:25:32.399
At this point, because the trial is kind of like on
cycles, and he's in cycle three now, I think literally is what it's called.
01:25:32.560 --> 01:25:32.800
Okay.
01:25:32.960 --> 01:25:35.680
And he understands cycle three at this point, but guess what?
01:25:35.840 --> 01:25:43.920
In I think two in a month and a half or two more months, he's gonna be in cycle four, and cycle four is gonna be different, and there's gonna be a new set of expectations.
01:25:44.079 --> 01:25:46.560
When he shows up, it's gonna be a different regimen.
01:25:46.720 --> 01:25:56.000
Yeah, and so now he's able to look ahead to say, okay, this is what's gonna take place next, and not have to just rely on whatever he's fed just in front of him right now.
01:25:56.239 --> 01:25:57.359
Yeah, and that's awesome.
01:25:57.520 --> 01:25:58.000
That's awesome.
01:25:58.079 --> 01:25:58.399
I love that.
01:25:58.560 --> 01:26:12.239
Well, and to your point about not trying to not throw every single question to a coordinator, because as you said, you know, they're all managing seven or ten other studies, and in that study visit, you know, uh, I think you've probably seen this.
01:26:12.319 --> 01:26:18.479
Like you asked the coordinator a question, and even though they're the coordinator, and coordinators are amazing and they run everything with research, right?
01:26:18.720 --> 01:26:21.439
Like, but they can't know every answer.
01:26:21.600 --> 01:26:28.079
No, like again, they're trained on the protocol, they're not necessarily trained on anything outside the protocol, right?
01:26:28.479 --> 01:26:28.880
That's right.
01:26:29.119 --> 01:26:34.800
It's it's it's very much unfair that we put everything that should be known on a coordinator.
01:26:34.880 --> 01:26:36.159
Um you're right.
01:26:36.319 --> 01:26:39.600
They do they do it all, and I think they shouldn't have to.
01:26:39.760 --> 01:26:46.399
And it's also basic things that I've found that my mom will search for, which could be something like is dizziness a side effect?
01:26:46.479 --> 01:26:47.439
Uh, I don't know if that's exactly.
01:26:47.600 --> 01:27:02.319
But she searches for a lot of things that like she'll notice that might yeah, because at this point, I don't know if something that's going on with him is could be related to the clinical trial, the the you know, the new drug that he's on, if it's just basic symptoms of his cancer at this point.
01:27:02.560 --> 01:27:04.159
And she's used that quite a bit.
01:27:04.319 --> 01:27:07.840
And her uh the the coordinator loves that.
01:27:08.079 --> 01:27:09.199
I want you to be proactive.
01:27:09.279 --> 01:27:21.520
And actually, now so one of the great things about clear trials is that the coordinators can see what they're searching, and so the coordinator can say, Hey, if you're dizzy and you're searching for this, let's talk because there could be something going on.
01:27:21.840 --> 01:27:23.359
Yeah, I I love that.
01:27:23.439 --> 01:27:25.279
I that is that's actually really cool.
01:27:25.359 --> 01:27:31.600
And you said earlier that one of the options people have is to just use chat or some other AI source.
01:27:31.760 --> 01:27:33.439
I mean, that to me is terrifying, right?
01:27:33.520 --> 01:27:40.720
Because that's happening every day, and people are using those kind of outlets for answers to real questions.
01:27:40.800 --> 01:27:48.319
And so some having something like clear trials that sort of is confined to this study information, right?
01:27:48.399 --> 01:27:52.399
Like they're that's they're not it's not like an extension of chat that they're using in this, right?
01:27:52.479 --> 01:27:56.479
Like this isn't gonna just give them weird information that you can find on the internet.
01:27:56.800 --> 01:27:57.039
Yeah.
01:27:57.439 --> 01:27:59.760
I mean, I I think one of the things that you'll find.
01:28:00.159 --> 01:28:03.600
Really quickly, if you use it, is that we're really quick to say what we can't answer, right?
01:28:03.840 --> 01:28:14.319
If you ask a question that's not answerable within the documents that you've been given, we say you should call your coordinator and ask them this question, or you can message them through the system.
01:28:14.560 --> 01:28:19.680
But to your point, it's it's a very confined guard-railed system.
01:28:20.159 --> 01:28:26.479
And unlike ChatGPT, it's going to try to answer your question, even if it's not in the consent form you've been given or the protocol.
01:28:26.560 --> 01:28:27.760
It'll say, Well, let me go try to.
01:28:28.079 --> 01:28:28.960
I want to make you happy.
01:28:29.039 --> 01:28:31.279
I want to give you an answer, even if it's not the right one.
01:28:31.520 --> 01:28:32.479
Yes, exactly.
01:28:32.720 --> 01:28:46.000
Yeah, no, that's uh yeah, that's terrifying that that's gonna be, and again, to you know, when we have situations like this where there are gaps in resources and people are looking for things, then you know, they're gonna go in places that they probably shouldn't go to get answers.
01:28:46.159 --> 01:28:50.239
And that should not be the case, especially in in research and healthcare spaces.
01:28:50.560 --> 01:28:51.039
Exactly right.
01:28:51.199 --> 01:28:54.640
So, so okay, so your dad's been in this trial for a little while now.
01:28:54.880 --> 01:28:58.399
What is his sort of and yours, I guess, too.
01:28:58.640 --> 01:29:00.079
What's your sort of take on this?
01:29:00.159 --> 01:29:05.840
I mean, it not necessarily is it a successful trial or not, but like has it been a good experience overall?
01:29:06.000 --> 01:29:08.960
Just thinking about the whole the whole situation.
01:29:09.760 --> 01:29:11.199
It it definitely has.
01:29:11.359 --> 01:29:19.439
I think if you were to ask myself, my dad, or my mom right now, who are kind of like his real support system.
01:29:19.760 --> 01:29:21.039
Are you glad you're in the trial?
01:29:21.199 --> 01:29:22.399
Do you regret getting in the trial?
01:29:22.560 --> 01:29:25.119
The
answer is most definitely we're glad that we've done it.
01:29:25.359 --> 01:29:35.920
If anything, I think it's really it's increased his and improved his relationship with everybody else around him who provides his care.
01:29:36.159 --> 01:29:39.039
He oh yeah, he he has a better relationship.
01:29:41.359 --> 01:29:44.640
He has a great relationship now with his doctor, with his nurses.
01:29:44.800 --> 01:29:48.479
Yeah, he sees them and he trusts them even more than he did before.
01:29:48.720 --> 01:30:00.399
It's I think with a lot of trials, it's bumpy at the beginning getting a participant consented and enrolled because it's it's it's tough.
01:30:00.560 --> 01:30:05.920
Participants are in a very scary spot, they have a lot of information thrown at them, they're overwhelmed.
01:30:06.239 --> 01:30:14.319
Once you get past that, there is a lot that's pushed on them, but we have resources to make it a better experience.
01:30:14.399 --> 01:30:16.239
And I think that's what my dad's seeing now.
01:30:16.319 --> 01:30:19.039
It's it's it's definitely worthwhile for him.
01:30:19.520 --> 01:30:26.640
And I know that I think his study ends, it's like it's probably almost six or seven months or something like that.
01:30:26.880 --> 01:30:34.319
And so it'll be very interesting to see after this, let's say he gets the opportunity to participate in another trial in the future, how that would go.
01:30:34.479 --> 01:30:42.000
Because I also think that being this is that that this is his first trial ever, and my first trial as a caregiver, yeah.
01:30:42.239 --> 01:30:46.239
Um, I I I also think that there's kind of a learning curve for everybody, right?
01:30:46.319 --> 01:30:52.239
And so maybe if we did this again and we were on trial number two, it might be it might be a totally different experience.
01:30:52.479 --> 01:30:53.039
Oh, well, sure.
01:30:53.119 --> 01:31:04.159
And and again, I think that's the I think you know you hear that because it happens on the research side, but uh on the patient side, I've heard that too, is that you know, people who have been in multiple trials, every study is a completely different experience.
01:31:04.319 --> 01:31:04.640
That's right.
01:31:04.800 --> 01:31:15.680
It's a completely different, and it's not, I mean, there's obvious reasons why you have different visits and different schedules and whatnot for the study, but I mean your study team changes, it's you know, you just never know.
01:31:15.760 --> 01:31:17.039
There's so many variables.
01:31:17.279 --> 01:31:26.159
And to your point, having anything that we can do to help the patient side be a little bit more a little easier, right?
01:31:26.319 --> 01:31:28.560
Like that's just shouldn't that be our goal?
01:31:28.800 --> 01:31:29.439
You know what I mean?
01:31:29.760 --> 01:31:36.079
Like all all of this stuff, it it's such a it seems like such an obvious benefit too.
01:31:36.159 --> 01:31:46.720
Like if we make not just agreeing to be in
a research study, but being in the study itself, like just staying in it, if we make that easier, everybody wins, right?
01:31:47.039 --> 01:31:54.560
The the we get enrollment numbers, we get the data that we need, we get the the you know, we find out if stuff works or it doesn't faster.
01:31:54.720 --> 01:32:01.600
Like it just seems like why aren't we putting more resources into the to that side to make that easier on them?
01:32:01.840 --> 01:32:02.800
That's exactly right.
01:32:03.199 --> 01:32:17.840
And and it's the last thing I'll say on this topic is that because people are searching for this like social aspect, like we said, the last thing you want is for somebody to reach out to you and they say, I had a terrible experience in a trial.
01:32:18.079 --> 01:32:30.319
I didn't have all the resources, and I showed up and I was told when I consented it was going to be a two-hour visit, and I was there for six hours, and they wasted my time and I couldn't find where to park and like all of these things.
01:32:30.479 --> 01:32:32.000
That's what we don't want to happen.
01:32:32.159 --> 01:32:35.520
And so absolutely yeah, no, that's great.
01:32:35.680 --> 01:32:36.079
That's great.
01:32:36.159 --> 01:32:38.560
I you know, Brian, I did want to ask you.
01:32:38.800 --> 01:32:44.880
You've done this now, you you've been the caregiver, right, for for your dad for a clinical trial now for a while.
01:32:45.119 --> 01:32:55.359
Going through everything you've gone through, I I mean, if there's people listening that are uh whether they're a caregiver for somebody else in a trial or they're thinking about it, maybe somebody in their family or friends are thinking about it.
01:32:55.520 --> 01:33:05.359
What kind of advice would you give to somebody that's a caregiver on this side of it to, I don't know, encourage or just kind of like, here's here are some of the hurdles I went through.
01:33:05.439 --> 01:33:06.079
You know what I mean?
01:33:06.319 --> 01:33:07.359
Oh, I do know what you mean.
01:33:07.520 --> 01:33:18.800
I think one of the biggest things that I would say is you're going to have to figure out a way to insert yourself into the the conversation.
01:33:19.119 --> 01:33:26.960
Um, the the the the caregiver existence right now, like we talked about, I think structurally is kind of ignored.
01:33:27.119 --> 01:33:32.399
It's very much a participant and a provider or a PI kind of relationship.
01:33:32.560 --> 01:33:32.720
Yeah.
01:33:32.880 --> 01:33:36.720
But with that being said, PIs and coordinators want that participant to show up.
01:33:36.800 --> 01:33:38.720
They want that, they don't want them to drop out.
01:33:38.880 --> 01:33:46.560
And so inserting yourself as the advocate, making sure that you say, hey, I'm the one who drives this person.
01:33:46.800 --> 01:33:49.439
I'm the one who sits with them every single day at home.
01:33:49.680 --> 01:33:53.600
When they have questions, I'm the one who helps them answer these.
01:33:53.920 --> 01:33:58.720
Fighting for yourself to be included in those conversations, I think is critical.
01:33:58.880 --> 01:34:03.039
And I don't think you actually have to fight that hard because the people want this to work.
01:34:03.199 --> 01:34:09.439
And so you just have to be, it just has to uh assert yourself as being part of this process.
01:34:09.680 --> 01:34:13.760
And when you do that, I think that you're going to get a much better experience.
01:34:14.000 --> 01:34:14.560
I love that.
01:34:14.720 --> 01:34:16.000
That is really good advice.
01:34:16.159 --> 01:34:18.560
And and I appreciate you sharing that for people listening.
01:34:18.720 --> 01:34:22.720
I think that's a really good takeaway that hopefully people can can take.
01:34:22.960 --> 01:34:26.880
But yeah, Brian, hey, I really appreciate you coming on the podcast.
01:34:27.039 --> 01:34:31.680
I appreciate you sharing your story as a caregiver and your and your dad's and and the whole experience.
01:34:31.840 --> 01:34:34.159
This has been a a great conversation.
01:34:34.399 --> 01:34:38.640
Oh well, I thank you for the opportunity, but also thank you for doing this podcast.
01:34:38.800 --> 01:34:44.239
I think it's really good to make sure that participants and caregivers are not left out of the conversation.
01:34:44.479 --> 01:34:50.800
So any chance that we can get to put them more at the center of things, I think is is great.
01:34:50.960 --> 01:34:51.840
So thank you for doing this.
01:34:52.079 --> 01:34:53.279
Oh, yeah, of course, of course.
01:34:53.359 --> 01:34:54.800
Well, you know, can't do it without you.
01:34:54.880 --> 01:34:59.600
So uh thanks for coming on, and uh yeah, hopefully people will get get a lot out of this.
01:34:59.920 --> 01:35:00.399
Awesome.
01:35:00.560 --> 01:35:01.600
Thank you, Justin.
01:35:02.079 --> 01:35:03.600
Thank you so much for listening.
01:35:03.680 --> 01:35:06.239
I hope you got something valuable out of these conversations.
01:35:06.399 --> 01:35:12.079
If you enjoyed the show, please be sure to follow, subscribe, or leave a review on your favorite podcast platform.
01:35:12.239 --> 01:35:15.760
For more information about our guest today, please check the show notes.
01:35:15.920 --> 01:35:24.720
I encourage everyone to check out our website at univodashgroup.com to learn more about how we are living into our mission of connecting more patients with research.
01:35:24.960 --> 01:35:26.159
Thanks again.